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Bone morphogenetic proteins (BMPs) are part of the transforming 
growth factor-β superfamily and function as key regulators of cellular growth, 
differentiation, and tissue formation. While recombinant BMPs can be used 
to induce osteoblast differentiation, they are expensive to produce. In 
contrast, peptides can be efficiently produced in massive quantities through 
phage display. It would therefore be highly valuable to develop short 
peptides capable of mimicking BMPs which could be displayed on human-
safe M13 phage. I have discovered the short, 12-mer peptide sequences 
TAKYLPMRPGPL, VHVPLHRGAVSA, SGTQDSMVGWNK, and 
RDYHPRDHTATW through a selective process called biopanning 
(patented). These 12-mer peptides have been shown to bind the BMP 
receptors on live cells by immunofluorescence and bind the BMP receptors 
in an ELISA when genetically displayed on the p3 coat protein of M13 
bacteriophage. The peptides were then genetically displayed on the p8 coat 
protein of M13 bacteriophage. The p8 coat protein can have up to ~2700 
copies of the peptide instead of just 5 available copies on the p3 coat 
protein. These newly engineered phages were incorporated into phage films 
having aligned ridge groove surface topographies which are arranged in a 
way that the p8 coat protein is exposed. Human mesenchymal stem cells 
(hMSCs) cultured on these films demonstrated varying levels of 
differentiation according to the peptide displayed as well as the 
concentration of the peptide. Differentiation of the hMSCs into osteoblasts 
was confirmed by immunofluorescence and qPCR of the osteoblast marker 
proteins and genes respectively for osteopontin, osteocalcin, and collagen 
xviii 
 
type 1a. Additionally, calcium deposition was observed to be exceptionally 
high for hMSCs cultured with the phage films compared to a leading 
company product, osteogenic media from Lonza. The mechanism of 
osteoblast differentiation for the two best peptides, VHVPLHRGAVSA and 
SGTQDSMVGWNK has also been determined through studying key target 
points as well as inhibition studies among the major osteogenic signaling 
pathways: BMP, Hedgehog, Wnt/β-Catenin, and Notch. These peptides 
follow two pathways, the Hedgehog and the BMP pathways independently. 
Additionally, the ridge groove 3D structure of the phage film contributes 
largely to differentiation through the Notch signaling pathway. The peptides 
displayed on phages were then directionally aligned on 3D printed porous 
titanium scaffolds using a double-sided freeze casting method. These 
scaffolds have Young’s moduli and maximum strength not significantly 
different from natural bone before and after implantation demonstrating no 
degradation. Upon implantation of the peptide displaying phage-coated 
titanium implants in a rat radial bone defect model, bone regeneration was 
observed through Micro-CT, Von Kossa Staining, and H&E staining. 
Furthermore, the peptide-coated scaffolds showed greater bone 
regeneration around and within the scaffolds. The success of this work 
establishes a new technique whereby growth factor mimetic peptides can be 








Chapter 1: Introduction 
 
1.1 Viruses as a material in nanomedicine 
Viruses come in a large variety of structures and properties which 
make them very useful for forming specialized structures in materials.1-7 For 
example, M13 bacteriophages are filamentous in structure and can exhibit 
liquid crystalline properties which allow them to be arranged by a pulling 
force into ordered structures upon drying.8-9 Even quasi-ordered 3D nano-
bundles can be made from M13 bacteriophages.10 Tobacco mosaic virus 
(TMV) is considered a rod-like virus or tubular structure.11 Due to its tubular 
structure, it is naturally useful in nanotube assemblies, but is also useful in a 
variety of other applications.11-15 Additionally, other viruses have icosahedral 
shapes such as with cowpea chlorotic mottle virus (CCMV).16 CCMV has 
180 identical coat proteins which assemble into a capsid having a 
triangulation number of T=3.16 A special property of CCMV is that it can 
disassemble and reassemble based on the pH and ionic strength of its 
surrounding environment. This can be highly useful for drug encapsulation 
strategies.16-17 In general, the various structures and properties of the many 
viruses play a key role in their applications as will be demonstrated. Several 













Figure 1. Viruses as a material in biomedical applications. Virus materials 
can be used in a number of applications such as vaccines, cancer therapy, 
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drug activation nanoreactors, disease diagnosis, drug delivery, and tissue 
regeneration. 
1.2.2 Structures of different viruses 
Several viruses’ shapes and sizes are shown in Figure 2. The shape 
and size of each virus plays an important role in its applications. For 
example, if the application was to make nanotubes, a tubular-shaped virus 
such as TMV would be a good template but an icosahedral shaped CCMV 
would be a poor choice.18 Additionally, shape and size can have major 
impacts for in vivo biomaterials. For example, even virus-like particles 
assembled from the same TMV coat protein can have significantly different 
circulation and clearance rates in vivo by varying their size and shape.19 
 M13 phage is a filamentous virus measuring roughly 9300 Å in length 
but having a diameter of just 65 Å.20 The M13 virion contains roughly 6407 
bases of circular single-stranded DNA encased in its coat proteins.20-22 Of 
the coat proteins of M13 phage, the pVIII is the major coat protein having 
roughly 2700 copies helically arranged to form the filamentous structure of 
M13 phage.23Additional surface proteins include pIII, pVI, pVII, and pIX.22-24 
 MS2 phage is an icosahedral virus with a capsid made primarily of 
180 copies of a coat protein shell.25 Inside the shell is a single stranded RNA 
molecule. Each of MS2 phage’s coat protein subunits come together to form 
a lattice having a triangulation number of T=3. This triangulation number is 
important as it describes the lattice of the major coat protein structure and 
structures often dictate the use of the virus in nanomaterials. The capsid has 
a diameter of 275 Å.25 
4 
 
 P22 phage contains a double stranded DNA (dsDNA) with ~40 
kilobases encapsulated by copies of a single capsid protein, gp5.26-27 The 
icosahedral capsid has a triangulation number of T=7. The P22 procapsid 
undergoes several morphogenesis steps to reach the mature P22 capsid 
stage including the attachment of a tail spike on the final, infectious form. 
The diameter of P22 phage is 700 Å.26 
 TMV is a rod like or tubular shaped virus.28 TMV is 3000 Å long and 
has a diameter of 180 Å. The central hole of the tubular shaped virus 
measures 40 Å in diameter.28 The outer capsid is made up of around 2130 
identical capsid protein subunits. Each subunit has a molecular weight of 
17,500 and comes together to make a right-handed helix. The helix has a 
pitch of 23 Å consisting of 49 subunits in 3 turns.28 The TMV RNA genome is 
made up of roughly 6400 single stranded, linear bases.29 
 The CCMV structure consists of 180 identical capsid proteins 
arranged into an icosahedral shell having a T=3 quasi-symmetry.30 The 
capsid measures 286 Å across (diameter) and encapsulates single stranded 
positive-sense RNA molecules.30 
 The grapevine fanleaf virus capsid consists of 60 identical coat 
proteins arranged in a pseudo T=3 symmetry.31-32 The icosahedral grapevine 
fanleaf viral structure measures 30 nm in diameter.31 The capsid contains a 
bipartite positive-sense RNA genome.31-32 
 The cowpea mosaic virus (CPMV) capsid has a diameter of roughly 
300 Å.33 CPMV has a pseudo T=3 surface lattice.33 The capsid consists of 
both L and S protein subunits. The capsid encapsulates one RNA of length 
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5889 (RNA1) nucleotides and another having a length of 3481 nucleotides 
(RNA2).33 
 T7 phage is an icosahedral shaped virus with a short, noncontractile 
tail.34 The capsid of T7 phage measures 60 to 61 nm in diameter.34 T7 
phages contain a 40 kilobase genome. The tail of T7 phages includes six 





Figure 2. Overview of the various structures of viruses commonly used in 




1.1.3 Biological properties of different viruses 
1.1.3.1. Chemical stability of different viruses 
The stability of viruses is an essential feature for their use as 
nanomaterials. Their inherent stability arises as a property of their structural 
organizations. To gain a better understanding of virus stabilities, first 
information about the viruses’ physical and geometric properties must be 
studied.35 The arrangement of the molecules making up a virus’ structure 
can be studied by electron microscopy or X-ray analysis. Once the viral 
structure is established, physicochemical observations can be done to study 
the assembly and disassembly of the virus. Lastly, by combining the study of 
physicochemical, chemical, and structural studies, more in depth information 
can be determined in regards to the specific noncovalent bonding which 
holds the virus together.35 
 TMV is a highly stable virus. Purified samples of TMV can be kept on 
a laboratory shelf for decades yet remain infectious.35 However, as with 
other viruses, the ribonucleic acid (RNA) within the TMV can be destroyed 
by a ribonuclease or heat inactivation.35 TMV does stay infectious even after 
being exposed to temperatures as high as 90 °C for 10 minutes.36 TMV is 
also highly resilient and stable for years in water. TMV even exhibits some 
stability in polar organic solvents such as methanol (stable 24 hours) or 
acetone (stable 3 hours).36 This stability in a variety of solvents can be very 
useful for chemical surface modifications. Within the intact TMV, the protein-
protein and protein-RNA interactions account for the inherent stability of 
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TMV.35 TMV is considered to be an ideal system for studying viruses as it is 
more stable than many other viruses.35-36 
 M13 phage is another highly stable virus.37 For example, M13 phages 
can withstand pelleting in a centrifuge, vigorous pipetting, and repeated 
freeze thawing cycles without losing any appreciable amount of infectivity.38 
M13 phages are also not susceptible to osmotic shock even upon dilutions 
from 4 M NaCl into distilled water.38 M13 phages can survive drying, and are 
resistant to denaturation by temperature. After being subjected to a 
temperature of 85 °C for 30 minutes, the infectivity of M13 phage only drops 
10-fold.38 
 T7 phages which are commonly used for displaying functional 
peptides or creating peptide libraries are also considerably stable. T7 
phages can survive being in 5 M NaCl.39 T7 phages can also survive in 4 M 
urea, 2 M guanidine-HCl, and 100 mM Dithiothreitol (DTT).39 T7 phages can 
survive a large pH range too (pH 4 to 10) which can make them an ideal 
virus to use in material applications. However, T7 phages can be rendered 
non-infectious with bleach or ultraviolet light.39 
 However, being highly stable, while desirable for many applications, is 
not always preferred. For example, CCMV virions have some interesting 
stability characteristics which can be exploited.40-41 While not considerably 
stable compared to other viruses, the wild type CCMV (with viral RNA intact) 
is known to be stable between a pH range of 3 to 6.42 CCMV is also stable 
under low ionic strength (I ∼ 0.1 M). An interesting property of CCMV is that 
it disassembles at high ionic strengths (I ∼ 1 M) at a pH above 7.42 In 
addition, the virus swells in size up to 10% when the ionic strength is low 
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(I < 0.1 M) at a pH above 7.42 A useful property for drug loading in CCMV is 
that the capsid proteins can be disassembled below a pH of 5 with an ionic 
strength between 0.1-0.2 M and then be reassembled by adjusting the 
conditions.42 The reassembled viruses will still have the same shape and 
morphology as the wild type CCMV, but they will be devoid of RNA.42-43 
However, if the CCMV is then used under physiological conditions additional 
stabilization techniques should be considered.44 Thus, it is important to 
consider the context of what application will be done with a virus when 
looking at its stability. Sometimes, very stable viruses such as M13 phage or 
TMV are ideal, but other times, encapsulation and reassembly strategies are 
far easier with less stable viruses such as CCMV. This will be an important 
concept to keep in mind when considering the applications of each virus. 
1.1.3.2. Monodispersity 
The monodispersity (not aggregated together) of viruses in a variety 
of solvents is highly important. In terms of dosages for medical applications, 
this is a necessity. In terms of consistently making well-ordered nanomaterial 
structures, this is also an important characteristic to have. While it has been 
discussed that viruses can be highly stable under a variety of conditions, 
they can also remain well dispersed and dissolved in a variety of solvents. 
For example, TMV can be dissolved in water, phosphate buffer, methanol, 
Dimethyl sulfoxide (DMSO) (80%), ethylammonium mesylate, and 
propylammonium mesylate.35 As another example, M13 phages are also 
stable and capable of being dissolved (in a monodisperse way) in some 
organic solvents.37 Lastly, the viruses discussed naturally dissolve in 
aqueous environments, making viruses a good material for consistent, 
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uniformly distributing applications.45-46 Such applications could range from 
creating even distributions of phage films, having consistent dosages to 
patients, and creating highly ordered electrodes for batteries.  
1.1.3.3. Biocompatibility 
The biocompatibility of virus-based materials is of great importance 
for medical applications. If a virus is to be used in vivo, how the immune 
system reacts as well as the fate of the virus should be known to avoid 
potential unintended side effects. The viruses described in Figure 2 do not 
infect humans, but they can still elicit an immune response in vivo. 
Sometimes, as with virus-based vaccines, this is an intended 
consequence.47 However, with other applications such as drug delivery, 
unintended immune responses are not ideal. It is known that viruses which 
do not naturally infect humans still illicit an immune response.48 Some 
viruses which do not infect humans such as bacteriophage phi X 174 are 
well established in terms of our immune response to them.48 However, not 
all of the viruses discussed in this review have been evaluated with such 
depth in humans. Still, several studies have been completed in animal 
models which have demonstrated a number of these viruses to be 
biocompatible.7, 49 For example, Pratik Singh et al. evaluated the 
biocompatibility of CPMV and found it to be a safe, non-toxic material for in 
vivo use.50 CPMV was found to have a rapid clearance from plasma (20 
minutes in a mouse model). After just 30 minutes almost all of the CPMV 
particles were trapped in the liver with some also in the spleen. No toxicity 
was detectable even at doses of 100 mg per kg body weight. However, 
elevated B lymphocyte levels were present on the first day of virus 
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administration, but they did subside quickly.50 Another virus used in many 
material applications is CCMV. Coleen R Kaiser et al. have evaluated the 
biocompatibility of this virus in mice.51 A broad distribution among most 
tissues and organs was found. CCMV was also rapidly excreted (within 24 
hours) and had no long-term persistence among tissues or organs. 
Additionally, no overt toxicity was observed after a single injection.51 M13 
phages have also been evaluated.52 The half-life of wild type M13 phages in 
plasma (of C57BI/6 mice) was found to be 4.5 hours. M13 phages primarily 
ended in the spleen and liver indicating uptake by the reticuloendothelial 
system.52 TMV is another virus that has been evaluated for biocompatibility 
by Michael A. Bruckman et al. in Balb/c mice.19 The rod-shaped TMV 
particles were found to be cleared by macrophages in the liver and spleen, 
eventually ending up co-localizing in B-cell follicles. The TMV particles were 
then cleared from the liver and spleen within days. No changes in histology 
were observed and no blood clotting or hemolysis occurred thus 
demonstrating the biocompatibility of TMV.19  Additionally, TMV has been 
coated in stealth proteins to study the effect on circulations time.53 MS2 
phages have also been studied in terms of biodistribution by Jacob M. 
Hooker et al. in Sprague–Dawley rats.54 MS2 phages cleared from the 
blood rapidly. It was demonstrated that less than 0.01% ID/g of [18F] 
fluorobenzaldehyde (chelated to MS2 phages) remained in the blood 3 
hours post-injection. MS2 phage particles primarily accumulated in the liver 
and spleen after 3 hours.54 With the amount of work done to evaluate the 
biocompatibility of several of these viruses, it is clear that viruses have the 
potential to be very good biomaterials. However, the limited data for 
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biocompatibility in humans is one issue that will need to be addressed in 
the future. Studies should also be done on longer term responses to 
multiple injections of viruses. Additionally, it is now understood that there is 
a widely diverse set of bacteria which symbiotically exist in the human 
gut.55 There will be a need to understand what effects introducing new 
viruses will have on this natural system. For example, will introducing a 
new virus upset the balance of bacteria? This is an essential question to 
answer as the field moves forward. 
1.2 Phages 
1.2.1 History and classification of phages 
One century ago, on September 3, 1917, Félix d'Hérelle announced 
he had “isolated an invisible microbe endowed with an antagonistic 
property against the bacillus of Shiga”.56 He called these antagonists 
“bacteriophages” (phages). Since this discovery, phages have been 
employed for several uses. For example, lytic phages were widely used as an 
antibacterial agent until the invention of antibiotics seemingly appeared to 
make them obsolete.57-58 However, with the development of antibiotic resistant 
bacteria, medical professionals around the world have resorted to employing 
lytic phages to treat common and antibiotic resistant bacterial infections.59  In 
spite of their immunogenicity, phages have been reported to elicit only a mild 
immune response, which gives promise to their potential use in humans.59 In 
fact, phage therapeutics is currently a very vibrant area especially in the 
context of the new clusters of regularly interspaced short palindromic repeat 
and associated genes (CRISPR/Cas) system and its ability to provide 
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selective pressure for antibiotic sensitive bacteria.60-65 Specifically, bacteria 
actively using the CRISPR/Cas system to fight off some phage infections have 
been shown to lose their antibiotic resistance.60-65 Indeed, even large scale 
human clinical trials have been completed or are underway such as the 
phagoburn (phase I-II clinical trials) project funded by the European Union 
under the 7th framework program for research and development.58, 66-67 The 
phagoburn project focuses on treating infections caused by burn wounds with 
professionally lytic phages, and is a large scale clinical trial utilizing phages in 
medicine. 
With the development of nanobiotechnology since 2000, using both lytic 
and temperate phages as biological nanoparticles have begun to fulfil a new 
role in nanomedicine. Precision medicine, ultrasensitive disease diagnosis, 
and targeted disease treatment in particular, have been greatly advanced by 
the emerging research with phages.68 At the forefront of these advancements 
are intricate systems in which the natural biology of phages is utilized in 
addition to enhancements via genetic engineering. Such integrated systems 
make it possible, for example, to invent new highly sensitive ways to detect 
diseases as well as create biomaterials that are a hybrid of genetically 
engineered phages and inorganic materials for targeted disease treatment. 
They also allow for precision targeting in drug and gene delivery because they 
can be genetically engineered to bear targeting molecules or be used as a 
platform for identifying targeting molecules. This precision targeting is 
particularly useful for diseases such as cancer in which standard methods of 




The lack of medicinal use of phages in the US and UK  to date has been 
attributed to a lack of acceptance by the mainstream scientific and medical 
authorities due to a lack of data from the Eastern European practitioners 
meeting Western standards for medical efficacy safety.59However, with 
present day increasing resistance to antibiotics and the pressing need for 
precision medicine, phages have become a versatile and extraordinary tool in 
nanomedicine. With promising new therapies available and the completion of 
several clinical trials, phage therapy has now been developed into a 
commercially viable technology. With this development, companies such as 
Pherecydes Pharma (based in the United Kingdom and France) have been 
leading the way to a new era of phage therapeutics.  
The versatility of phages in nanomedicine in regard to precision targeting, 
self-assembled biomaterials, and many more techniques is in large part due 
to the natural biology and structure of phages. From a biological perspective, 
phages are a virus that specifically infect bacteria. They are classified 
taxonomically into families, but due to the rapid changes in the established 
taxonomies from year to year, the most current existing taxonomical families 
should be referenced according to the international committee on taxonomy 
of viruses.59, 69 Each family is assorted according to the structure of their 
capsids encompassing their genomes, the chemical and structural 
composition of their genomes (linear, circular, double, or single stranded, DNA 
or RNA), and the mechanism of mRNA production.59In terms of making use 
of phage biology, there are several reviews encompassing phage display70-78 
and bacterial biosensing79-80. Phage display is useful for finding peptide 
ligands that can specifically bind to disease associated receptors and 
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microenvironments.59, 81 Additionally, nanotechnology often employs the use 
of phage morphologies such as the naturally occurring filamentous structure 
of M13 phages.  
1.2.2 Life cycles of phages: temperate vs. professionally lytic 
 Phages exist in various shapes and sizes from long rod-like filaments 
to more compact shapes with much shorter tails. A few representative phages 
are shown in Table 1. Despite their many differences, two broad categories, 
professionally lytic or temperate phages are sufficient to briefly understand 
phages (Table 1).82 In essence, professionally lytic phages break open and 
kill the host bacteria when they infect bacteria to get amplified and then leave 
the bacteria. However, temperate phages do not kill the host bacteria when 
they infect the host bacteria; instead, they only use the host bacteria as a 
factory to be amplified and finally get secreted from the host. Additionally, it 
should be noted that some phages share qualities from both categories. For 
example, the term professionally lytic refers in particular to the predominant 
lifestyle of being lytic but that does not mean that this phage type cannot have 
phages capable of having temperate qualities.82 For example, the temperate 
phage called lambda is one such phage. Infection by Lambda phage begins 
when the phage attaches to the host cell and injects its DNA into the cell. From 
here, the phage either enters the lytic or lysogenic cycle.83 If followed, the lytic 
cycle involves the immediate replication of the phage DNA by bacterial 
machinery. The DNA templates are then used for production of phage 
proteins, which are assembled into phage particles. When phage particles 
build up, the cell undergoes lysis and is broken into fragments.84The phages 
are then released and begin infecting additional bacteria. 
16 
 
Upon viral DNA entry into the bacteria cell, the phage DNA may also enter 
the lysogenic cycle. In the lysogenic cycle, viral DNA integrates into the host 
genome through recombination, producing a prophage. Although a less 
common path, the lysogenic pathway can be followed when conditions are 
unfavorable for bacterial cell replication. Thus, this phage can also have 
temperate qualities. The prophage is then replicated each time the bacterial 
cell replicates. In lambda phage, to prevent a phage from being cut out of the 
genome and entering the lytic cycle, the lambda repressor is synthesized from 
the transcribed cI gene product and occupies the OR1 and OR2 sites.85-87 This 
represses the cro gene. If conditions make cell death likely, the repressor 
protein is cleaved in half by recA (from the cell’s distress response to DNA 
damage) and the cro gene is derepressed.85, 88The cro protein is created and 
occupies the OR3 site, turning off transcription of the cI gene.85 This allows the 
prophage to be cut out of the host genome and enter the lytic cycle. 
 Professionally lytic phage types are generally composed of a head and 
flexible tail, but lack the long filamentous shape shared by most temperate 
phages. These phages primarily resort to lysing the host cells during the 
infection cycle and some key examples of professionally lytic phages include 
T1-T7 phages.82 These phages are often used in phage-based antibacterial 
strategies. An example of a professionally lytic phage is T7 phage. T7 phage 
is a member of the Podoviridae family and has an icosahedral head with a 
short tail. When T7 phages infect cells, several internal capsid proteins get 
ejected into the host cell wall and assemble an ejectosome allowing for the 
translocation of DNA from the T7 viral capsid into the cell.89 The viral DNA 
immediately begins a process in which a set of proteins necessary for 
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replicating the phage DNA are transcribed and translated from the viral DNA 
template. This results in several copies of the viral DNA being made.89 Next, 
a second set of proteins are made and assemble into the various structural 
components of the phages. Lastly, while the assembly process is taking place, 
lysozyme is produced. The lysozyme will lyse the host’s cell wall and allow for 
the release of the mature viruses.90 This whole process is actually quite fast 
and depending on the fitness of the phages; It can take just a matter of minutes 
to complete.91 Therefore, professionally lytic phages have gained a lot of 
attention in antibacterial applications. 
The temperate inoviruses are filamentous phages including the Ff, M13, 
f1, fd, Ike, and N1 phages.59 So far, filamentous phages have found more 
applications in templating nanomaterials synthesis than professionally lytic 
phages, probably because filamentous phages tend to be used to template 
nanowires synthesis and self-assemble into higher-order structures. 
Filamentous temperate phages can be pictured as a long flexible nanofiber 
composed of five structural capsid proteins, which encase a relatively large 
circular single strand of DNA.23, 92One example includes wild-type M13 (Table 
1), which measures ~9300 Å long, but has a diameter of only 65 Å.20The M13 
virion consists of ~6407 bases of circular single-stranded DNA (ssDNA) in its 
genome, but longer genomes generate longer phages.20-22Although there are 
five different proteins, the majority of a filamentous phage is coated by ~2700 
copies of a protein encoded by a single gene called pVIII,23 which is helically 
arranged to form a filament tube.92This is the protein that is often modified for 
desirable characteristics in the lab, and the filamentous temperate phages can 
serve as a highly structured nanomaterial. The ends of filamentous phages 
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are composed of minor coat proteins. One end is composed of five copies of 
the proteins pIII and pVI, while the opposite end displays five copies of the 
proteins pVII and pIX.22-24The filamentous structure and major coat proteins 
are what makes these phages capable of creating many self-assembled 
nanostructures as well as develop excellent targeting abilities. 
Unlike professionally lytic phages, filamentous phages are secreted from 
bacteria without bacterial cell lysis.23, 92Filamentous phages infecting 
Escherichia coli are among the most productive phages and can produce titers 
of up to 1013 phages per milliliter of culture.92The infection cycle begins when 
the minor coat protein at the tip, pIII, utilizes its N2 domain to bind to the F-
pilus on the surface of a bacteria cell.93 The F-pilus will then retract, pulling 
the phage closer to the surface of the bacterium.20, 93-94Next, it is thought that 
the N1 domain of pIII binds to the TolAIII domain on the highly conserved inner 
membrane complex, TolQRA.92-93 Interaction of the C domain of pIII with the 
TolQRA complex or some conformational rearrangement of the C domain of 
pIII then exposes the hydrophobic C-terminal helix of pIII, allowing insertion of 
the helix into the inner membrane.92Finally, the phage ssDNA is injected into 
the cytoplasm, where it can either begin replicating (episomal) or integrate into 
the host’s chromosome (temperate).92 If the ssDNA goes the temperate route, 
it becomes a substrate for XerCD recombinase, which will bind to the forked 
hairpin loop termed AttP92 and integrate the viral DNA into the bacterial 
genome through site-specific recombination at the dif site located between the 
chromosomal DNA and a previously inserted satellite phage such as RS1φ or 
TLCφ.95This process is called lysogenization. After integration into the 
chromosome, there may come a time when it is beneficial for the virus to 
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undergo induction. Such an event could occur if the cell undergoes damage 
as shown in experiments using UV light or Mitomycin C, which will incite a 
cellular SOS response in which LexA is degraded.92This results in PA promoter 
transcription, which will eventually lead to the releasing of the recirularized old 
ssDNA, which is a combination of the satellite and prophage between the two 
origins of replication. It is important to note the resulting replicon is not the 
same as the one initially integrated into the chromosome.92The ssDNA can 
then replicate by the episomal path. 
Negative strand synthesis of the ssDNA is carried out by bacterial RNA 
polymerase, which will first generate an RNA primer that is subsequently 
released from the template ssDNA.96 Bacterial DNA polymerase III then 
creates a replica of the negative strand based on the RNA primer sequence. 
The positive strand synthesis is then initiated by the non-structural phage 
protein pII. Supercoiling occurs on the double-stranded DNA (dsDNA), which 
forms a stem-loop structure that allows a nick in the positive strand of the 
dsDNA to be created at the origin of replication.92Rolling circle replication then 
completes the new copy of viral DNA.97 The copies of the replicative form of 
viral DNA then serve as a template to produce the non-structural phage 
proteins pII, pV, and pX to help with packaging of the substrate and genome 
replication.20, 92Non-structural proteins pI, pIV, and pXI are also created from 
the replicative form using bacterial cell machinery and form a transport 
complex spanning the outer and inner membrane of the bacteria cell. The 
phage structural proteins pVII, pIX, pVIII, pVI, and pIII are then inserted into 
the membrane for latter assembly into the phage virion.24, 92 The positive 
strands of viral DNA are then coated by dimers of the ssDNA binding protein, 
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pV, and transported to the cell membrane for packaging by the transport 
complex and assembled into the exported virion form of the phages.20, 92 
 
Table 1. Various structures and applications of phages in nanomedicine (Reproduced 
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Podovirus P22 of Salmonella typhimurium at X 
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CryoEM map of a Ф29 phage. High densities are 
white and low densities are black. The various 






































Cryo-electron micrographs of wild-type PRD1 
phages mixed with a preparation of susI 
packaging mutant at 2 µmunderfocus. The arrow 
points to a DNA filled phage particle and the inset 
shows a particle which has lost its DNA and 























1.3 Virus-derived peptides for biomedical applications 
The proper diagnosis and treatment of illnesses is of vital importance 
worldwide. For example, cancer is a major cause of human death 
worldwide.128 In the United States, ~25% of deaths are caused by cancer. 
There were a projected 1,660,290 new cancer cases and 580,350 deaths in 
2013.129 In China, according to the National Death Survey conducted by the 
Ministry of Health, cancer is currently the second leading cause of death due 
to increasing cancer mortality rates in the past years.130 However, cancer 
patients are just one of many disease groups that can benefit from swift 
diagnoses and targeted treatments. Pathogens are another major cause of 
death. More than 9 million pathogen related illness diagnoses are due to 
foodborne pathogens in the United States alone.131 Bacterial pathogens such 
as Salmonella enterica and Listeria monocytogenes alone account for $3.3 
billion and $2.6 billion in medical costs a year in the United States, and this 
only scratches the surface. It is estimated that just 14 foodborne pathogens 
account for $14 billion a year in medical costs for the United States.132 Among 
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other pathogens, fungal infections such as those caused by Candida albicans 
and Paracoccidioidesbrasiliensis, can also be devastating. It is estimated that 
the most common fungal diseases in humans affect ~1.7 billion (or roughly 
25%) of the general worldwide population. Despite the current availability of 
antifungal drugs, invasive fungal infections often have mortality rates 
exceeding 50%.132 Additionally, viral diseases such as orthopoxviruses 
(cowpox and monkeypox) infections, avian influenza A, and parasitic illnesses 
such as malaria or schistosomiasis are also devastating.133-137 Hence, there 
is an overwhelming need for disease detection and therapeutics. These 
techniques must be both more effective than currently lacking techniques and 
cost-effective so that they may be used more widely around the world. This 
section will describe cutting edge techniques for disease detection and 
therapeutics centered around the development of short organism-binding 
peptide sequences developed through virus-peptide display technology.  
Over the past decades, researchers have put forth a huge effort and 
investment towards developing affinity agents, including antibodies, proteins, 
peptides and nucleic acids.138-146 The use of peptides now has an ever 
expanding role with unexpected applications and has even been implicated in 
virus communication to name just one unique role.147 For example, it has been 
shown that phages can communicate with each other to make a group 
decision in regards to their life cycle using a peptide.147 It would be of great 
importance to discover whether or not more dangerous viruses react in a 
similar manner.  Among these applications, peptides possess several 
advantages in biomedical applications.148-153 First, peptides can be easily 
obtained by chemical synthesis with a high yield and low cost. Second, due to 
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their small molecular weight, peptides (~10 amino acids long) can enter cells 
and penetrate tissue easily, be cleared in the blood rapidly, are quickly 
metabolized, and have a low immunogenic nature. Another advantage is that 
peptides do not need to be produced in animals or with cells which makes 
them more ethical as well as economical than antibody development 
techniques.153 These advantages make peptides very appealing for 
biomedical applications, such as molecular imaging, disease diagnosis, and 
therapy.  
Organism-targeting peptides, which can selectively bind to a specific type of 
organism with high affinity, have been derived from several different origins. 
One way to discover organism-targeting peptides is to use peptides that are 
ligands for specific cell-surface receptors. A good example of this is RGD (Arg-
Gly-Asp) and its derivatives.154-158 RGD is also one of the first tumor-homing 
peptides which was discovered by randomly synthesizing portions of the 
amino acid sequence from fibronectin.159-160 RGD shows a high selectivity and 
strong affinity to the integrins that are highly expressed on the surface of some 
kinds of cells such as cancer cells and is useful in a number of applications.161-
164 This method of identifying peptides is based on guessing and checking, 
which can be very cumbersome for larger peptide sequences. Therefore, 
more efficient methods have gained interest. Some of the most effective 
strategies for discovering novel targeting peptides are evolutionary screening 
virus-peptide display techniques.165-167  For example, through biopanning with 
phage, the well-known RGD motif has been rediscovered by Wadih Arap et 
al. where it is part of a longer sequence, CDCRGDCFC.168 This has become 
a famous sequence now called RGD-4C.168-170 Despite the massive potential 
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impact of such treatments worldwide, this topic of combining biopanning with 
peptide-based treatments is relatively new and upcoming and has thus not yet 
received much attention. Table 2 gives a few examples of human clinical trials 
involving virus-derived peptides. Additionally, an overview of the available 
virus-derived peptides can be found in Table 3 (pathogen targeting), Table 4 




Table 2. Examples of Virus-derived Peptides in Clinical Trials for Humans 
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Table 3. Pathogen-targeting peptides derived from virus libraries 
 Pathogen  Viral Library 
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Table 4. Summary of human cell-targeting peptides derived from virus libraries 
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Table 5. Summary of tissue-targeting peptides derived from virus libraries in preclinical or 
clinical trials 
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1.3.1 Viral Libraries 
Virus-peptide libraries are a mixture of millions of virus particles where 
each virus displays a unique and random set of peptides. There are two major 
types of viral libraries, one based on non-lytic or lytic bacteriophages (phages) 
and another based on adeno-associated viruses (AAV). Filamentous fd and 
M13 phages, which are non-lytic bacteria-specific viruses (and very similar in 
structure and morphology to each other), are the most widely adopted phages 
in phage display techniques likely due to their commercial availability.75, 228-230 
They have a rod-like shape that is ~800 nm in length and ~6 nm in width 
(Figure 3).231 The circular, single-stranded DNA genome is surrounded by a 
protein sheath consisting of ~2700 copies of one major coat protein (pVIII), 
and five copies of four minor coat proteins (pIII and pVI on one tip, pVII and 
pIX on the other tip).232 These coat proteins are encoded by corresponding 
genes located in the DNA genome. Foreign DNA that encodes for foreign 
peptide expression can be inserted into the phage genome to display any 
desired peptides on the surface of the protein sheath.166, 233-234 In other words, 
a foreign peptide can be fused to minor and/or major coat proteins to site-
specifically display at the end and/or along the side wall of phage particles by 
DNA engineering methods. Lytic phages such as T7 phage have also become 
widely used.39, 235-237 Since phage display was introduced by George P. Smith 
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in 1985 238, this technique has proved to be one of the most powerful 
approaches for selecting affinity ligands, including cell/tissue and pathogen 
targeting peptides.239 Nowadays, phage display has been further developed 
in combination with other techniques, such as microfluidics or better analysis 
software, to improve its selection efficiency.193, 240-242 The most widely used 
phages for phage display are shown in Figure 3. 
 
 
Figure 3. Phage display on M13 and T7 phages. For M13 phage, the 5 copies 
of pIII are usually utilized in phage libraries for biopanning. After a desired 
targeting sequence is obtained, that sequence may be genetically engineered 
into another M13 phage to be displayed on the much more plentiful pVIII. 
Biopanning is frequently done with pIII rather than pVIII for M13 phages. 
Stronger binding sequences will be obtained using only 5 copies of pIII vs 
using a large number of weak binding pVIII. For T7 phage, the capsid is 
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composed of 415 copies of the coat protein 10A and/or 10B. Through phage 
display, ~5-15 copies of the genetically engineered peptide sequence will be 
displayed on the C-terminus of capsid 10B.243 (Reproduced with permission 
from American Chemical Society) 
1.3.2 Selecting Targeting Peptides by Virus-peptide Display 
 
Targeting peptides can be selected by allowing the aforementioned 
viral libraries to interact with the target organisms in vitro, ex vivo, or in vivo. 
In addition, biopanning can be more generally carried out on any target which 
does not have to be a biological target. The general procedure for biopanning 
is shown in Figure 5 while the in vivo procedure is shown in Figure 4.  By using 
such a virus-peptide display technique, virus-derived peptides targeting 
pathogen (Table 2), human cells (Table 3) and tissues (Table 4) can be 
discovered and widely applied in human disease diagnosis and therapy. 
Cell/tissue-targeting peptides can be selected from a phage library 
containing up to 109 phage clones, each clone displaying a unique and 
random peptide, through an evolutionary screening process called 
biopanning.165, 233, 244-245 The general biopanning procedures for discovering 
cell/tissue-targeting peptides from a phage library are as follows.190, 246-248 
First, an input phage library containing billions of phage clones with randomly 
displayed peptides is incubated with target cells or tissues. Some phages bind 
to and/or internalize into target cells/tissues while others do not during 
incubation. Second, a washing buffer is used to remove the weakly bound and 
unbound phages from the cell/tissue surface. Third, the cell/tissue-targeting 
phages are eluted from the target cells/tissues using an elution buffer. Fourth, 
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the eluted cell/tissue-targeting phages are biologically amplified by infecting 
E. coli bacteria which are cultured and used to enrich the selected phages. 
The process from step one to step four is designated as one round of 
selection. The enriched library is considered as an output for the previous 
round. The enriched library is used as a new input for the next round of 
selection. After 3-5 rounds of selection, the foreign DNA insert-coding region 
in a phage genome is sequenced to determine the peptides that are 
expressed on the phages. The amount of rounds to use can be determined by 
sequencing each round and checking the diversity of peptides still present. A 
diversity of 20 peptides in which several are more frequent is best. This 
quantity helps avoid bias in selecting peptides which are better at amplifying 
rather than binding the target of interest. This is possible because the 




Figure 4. In vivo phage biopanning concept. A phage library displaying 
roughly one billion different combinations of peptides is injected into an animal 
model. Phages can migrate to their target organs, tissues, receptors, disease 
cells, etc. for which their peptides have the highest affinity. The phages are 
then recovered from the animal model by harvesting the desired target, such 
as a specific organ. The phages are then amplified and go through additional 
rounds of selection. After 3-4 rounds of selection, phages are sequenced to 
identify the high-affinity peptides achieved. (Reproduced with permission from 
American Chemical Society) 
 
 
Figure 5. Summary of the process of biopanning. Briefly, a target ligand is 
immobilized on a surface. A bacteriophage library can then be washed over 
that surface (a negative selection for the surface without ligand should also be 
done first) after which only those phages displaying peptides that bind the 
target will stay bound. The surviving phages can then be released by 
42 
 
disrupting the interaction. Released phages can be amplified and the selection 
can be repeated, usually 3 to 4 times. At the end, phages can be titered and 
individual plaques can be picked to be sent for sequencing. The most 
frequently occurring peptides identified from sequencing are then presumed 
to be the best at binding the target ligand. (Reproduced with permission from 
John Wiley and Sons) 
1.3.3 Virus-derived tissue regenerative peptides 
The versatility of virus-derived peptides for diverse applications also 
extends to discovering new tissue regenerative peptides.8, 249 For example, 
Caprini et al. developed a short peptide, KLPGWSG, which binds to neural 
stem cells and enhances differentiation toward the neuronal phenotype. The 
peptide was developed through biopanning with an M13 phage Ph.D. 7 library 
(New England Biolabs). The differentiation effects were characterized via 
rheometry and circular dichroism, atomic force microscopy, and assessing 
differentiation of cells in nanostructured hydrogels. Additionally, virus-based 
techniques can be used to better isolate the most effective peptides among 
known tissue regenerative peptides. For example, we displayed several 
osteoblast inducing peptides on M13 phages to test the effects of each 
peptide.8 The comparison involved the peptides RGD, RGD/PHSRN (double 
displayed), ALKRQGRTLYGFGG (osteogenic growth peptide), and 
KIPKASSVPTELSAISTLYL (from bone morphogenic protein 2). By creating 
phage films out of these different genetically engineered M13 phages, these 
peptides were able to be compared side by side in a relatively easy and cheap 
manner. This was done by culturing stem cells on the different phage films. 
By comparing the results of quantitative real time PCR as well as the 
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immunofluorescence of marker genes and proteins respectively, the 
effectiveness of each peptide could be assessed. The results demonstrated 
that the peptides ALKRQGRTLYGFGG and KIPKASSVPTELSAISTLYL were 
the most effective at differentiating induced pluripotent stem cells into 
osteoblasts. While this technique is not the typical biopanning method, it 
demonstrates an alternative way to derive clinically relevant peptides from 
using viral techniques. 
1.3.4 M13 Phage assemblies for tissue regeneration 
There are also numerous examples of using M13 bacteriophages in 
other ways for tissue regeneration. One frequently used technique is to 
assemble bacteriophages into a phage film.8 The nanotopography of the 
phage film can help induce the differentiation of stem cells into a desired 
mature cell type.8 Additionally, genetically displaying peptides on the phage 
films allows for the activation of signaling pathways which further enhances 
differentiation.8 Alternatively, the phage itself can be incorporated into 
scaffolds as a nanofiber.158 When signaling peptides such as RGD are 
incorporated into these scaffolds (perhaps made from 3D printing or other 
methods), tissue regeneration has been shown to be enhanced.158
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1.4 3D printing for tissue regeneration 
The need for both tissue regeneration and organ transplants worldwide is 
staggering.250-254 For some patients, it can be more beneficial to accept an 
organ such as a kidney from a donor with diabetes than it can be to remain on 
the waiting list for a lengthy time.255  In addition, patients may have 
incompatibility issues with available donated organs creating more 
complications.256 At the forefront of regenerative and replacement strategies to 
combat these issues is 3D printing.257-259 In recent years, 3D printing has 
progressed to be capable of reproducing some of the most complex biological 
structures down to the cell niche.260 For example, cardiovascular tissues, aortic 
valves, skin, bone, liver, brain, muscle, cartilage, kidney, ovary, tumor, and 
adipose tissues are all being worked on with novel 3D printing strategies.261-
272There have been numerous of reviews which cover the technical aspects of 
3D printing including software usage and the mechanical properties of 3D 
printers as well as the available materials to use in 3D printing.273-277 Figure 6 





Figure 6. Summary of 3D printed tissue examples for biomedical applications. 
3D printing can be used to fabricate skin tissue, aortic valves, cardiovascular 
tissue, bone, brain tissue, adipose tissue, tumors, kidneys, cartilage tissue, 
muscle tissue, livers, and promote vascularization in these printed constructs.  
1.4.1 Materials Used in Biomedical 3D Printing 
There is a nearly endless supply of options for materials to use in 3D 
printing. The material used depends on the application. For example, if 3D 
printing is only being used as a way of creating a model for presurgical planning 
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or mold for another application, cheap plastic materials such as polylactic acid 
or acrylonitrile butadiene styrene are often used.278-280 For certain tissue 
regenerative strategies such as those dealing with bone, various inorganic 
materials such as Ca7MgSi4O16 or titanium alloy (Ti-6Al-4V) have gained 
attention as well as others.262, 281-282 When it comes to incorporating live cells 
into materials, hydrogels are the primary choice.283-285 Some popular hydrogel 
options include the individual components or combinations of alginate263-264, 270, 
286-289, gelatin263, 270, 288, chitosan264,  fibrinogen270, 288, collagen263, 265, 
methacrylated chondroitin sulfate290, agarose291, polyethylene glycol283, 292-293, 
and hyaluronic acid294-296. Another bioink-hydrogel based option also exists 
which incorporates virus into a hydrogel.297 This bioink, created by Doe-Young 
Lee and Hyeongjin et al. incorporated genetically modified M13 bacteriophages 
into a hydrogel.297 By genetically altering the M13 bacteriophages to double 
display the GRGDS (from the famous RGD peptide sequence which can 
enhance osteoblast differentiation) and DDYD (which is a calcium-binding 
peptide) a virus-based bioink for bone tissue regeneration applications could be 
created.297-299 In addition, 3D printing materials can incorporate antimicrobial 
drugs such as anti-microbial nitrofurantoin or 3D printing can be used to print 
the drug itself onto a substrate.300-301 With so many material options available to 
use in 3D printing, it is important to consider the details of the desired 
application before choosing which materials to print with. 
1.4.2 Vascularized bone regenerative 3D printing 
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The vascular system should not be thought of separately from all other 
tissues and organs. In fact, all 3D printing for tissue regeneration having 
scaffolds thicker than 100 µm (depending on cell type as some cells such as 
cartilage cells are more robust) must consider the vascularization of the tissue 
construct.302 Without vascularization, nutrients, oxygen transport, and waste 
discharge are at the mercy of diffusion.302-303 This is a major problem for cells. 
Most cells do not survive at distances greater than 200 µm from a blood 
vessel.302 More sensitive cells such as islets show necrosis at just 100 µm.302 
Still, there are some more robust cells such as cartilage which can live up to 1 
mm away from the nearest blood vessel.302 To date, vascularization strategies 
in 3D printing have been a hot topic.263, 303-309  One known strategy for 
organizing endothelial cells into microtubes which then form blood vessels is to 
include microchannels in the 3D material.262, 310-311 For example, Wenjie Zhany, 
Chun Feng, and Guangzheng Yang et al. developed a 3D printing microchannel 
material having a hollow-pipe-packed structure containing silica, magnesium, 
and calcium (Ca7MgSi4O16) as a bioceramic material.262 The hollow struts could 
be 3D printed with an internal diameter of 500 µm and an external diameter of 1 
mm. The material had a compressive strength of up to 26 MPa. The bioactive 
ions within the material had multiple purposes. Previous studies have 
demonstrated that silica ions can enhance vascular ingrowth as well as exhibit 
a capacity for osteogenic induction.262, 312-313 The magnesium ions are 
considered to directly influence vascularization and bone regeneration.262, 314 
Thus, as one might expect, this material is an example of both vascularization 
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with 3D printing and bone tissue regeneration.262 The hollow-pipe-packed 
structure was then seeded with rabbit bone mesenchymal stem cells and 
implanted into a rabbit radial bone defect model. The hollow-pipe-packed 
structure significantly promoted the rapid infiltration of the host’s blood vessels. 
Additionally, they allowed for better delivery of stem cells and growth factors 
which enhanced tissue regeneration. Radiological and histological findings in 
the rabbit radial bone defect model further showed that the 3D printing construct 
could enhance early vascularization as well as long-term bone regeneration. 
This work demonstrates just one of the many unique ideas currently being used 
in 3D printing for improving vascularization. This will continue to be an important 












Chapter 2: Development and discovery of peptides capable of 
binding and detecting bone morphogenic protein receptors 
2.1 Introduction 
Growth factors are abundant in human bodies, such as bone 
morphogenic proteins (BMPs), insulin-like growth factors (IGFs), and vascular 
endothelial growth factor (VEGF).315-317 They are important in organ 
development and tissue regeneration. They are proved to be capable of 
inducing stem cell differentiation. For example, BMP2 and VEGF can induce 
hMSCs to differentiation into osteoblasts318-319;  IGF-I can induce quiescent 
neural stem cells to differentiation into neurons.320 Growth factors are normally 
produced by recombinant protein engineering or purified from animals making 
them expensive or immunogenic.  For instance, recombinant BMP-2 costs 
about $3,500 for 1 mg. In addition, the growth factors are usually large proteins. 
They are added to the tissue regeneration scaffolds by either mechanical 
mixing or chemical conjugation with the scaffolds. However, to conjugate a 
growth factor with a scaffold relies on a tedious and complicated procedure and 
may render the growth factor not functional due to the blocking of some 
functional domains.321 Procedures such as amine coupling for growth factors 
(e.g., BMP-2) have been used, but these procedures also do not control the 
orientation of immobilized protein.322 The immobilization strategy can also 
influence the rate of growth factors release.321 Problems can also arise when 
growth factors such as BMP-2 leak outside of target areas and cause unwanted 
side effects as was the case in spinal patients.323 With short functional peptides, 
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greater control over the orientation and access of the peptides to targets can be 
achieved during the immobilization process. This may help alleviate some of the 
issues involved with using full proteins. Thus, there is a pressing need for a 
cheaper and simpler substitute for a growth factor to be used in regenerative 
medicine. 
Short peptides have various advantages in biomedicine compared to 
proteins.324-330 Peptides can be easily synthesized in high yields, high purities, 
and at low costs. Short functional peptides such as the ones made of about ten 
amino acids are much cheaper and simpler than proteins (e.g., 396 amino acids 
constituting human BMP-2). More importantly, they are much less immunogenic 
than growth factors isolated from other sources and produced in a recombinant 
way.330  For example, leakage of BMP-2 from the intended location in spinal 
patients has caused 35 out of 151 patients (23.2%) to experience adverse side 
effects such as hematoma, difficulty swallowing, breathing problems, or 
dramatic swelling.331 These effects are likely due to diffusion of BMP-2 outside 
of the intended surgical location.323, 331 Since growth factors function by binding 
to their receptors on the cells, we propose to search for growth factor-like short 
peptides that can bind to the same receptors by using BMPs as model growth 
factors. 
BMPs are one member of the transforming growth factor-beta (TGF-) 
superfamily and participate in bone extracellular matrix (ECM) development.332-
336 Among different BMPs, BMP-2 was found to induce osteogenic 
differentiation of stem cells337 and promote bone formation.338 BMP-2 forms 
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dimers, which bind to type I and type II BMP receptors (BMPR1A and BMPRII) 
on the cell surface to initiate osteogenic differentiation. BMP-2 signals go 
through heteromeric complexes of transmembrane receptors (BMPR1A and 
BMPR2332-336,339). Upon activation of these receptors by BMPs, a Smad 
signaling pathway is triggered, resulting in the phosphorylation of R-Smads 
(Smad1/5/8). After the phosphorylation is finished, R-Smads are dissociated 
from the receptor and then complexed with Smad4. The complex enters the 
nucleus of the stem cells, activating their osteogenic differentiation.340 Since 
BMPs bind and recognize two types of BMP receptors (BMPR1A and BMPR2) 
to trigger the osteogenic differentiation, we employed phage display to identify 
BMPR1A and BMPR2-binding peptide domains. Our hypothesis is that BMP 
receptor-binding peptides may potentially mimic BMPs in inducing osteogenic 
differentiation since BMPs bind the same receptors to perform the desired 
functions.  
2.1.1 Phage display for identifying receptor-targeting peptides.  
M13 phage is a human-safe natural biopolymer nanofiber composed of 
~3000 highly ordered copies of the major coat protein (p8, made of 50 amino 
acids) surrounding a circular ssDNA.341-342 M13 phages have received a BSL-1 
risk assessment rating in relation to human health.343 The DNA encodes coat 
proteins including p8 on the major coat (i.e., side wall) and four other structural 
proteins at the two tips (called minor coats) such as p3. By inserting DNA 
encoding peptides into the genes of the coat proteins, the peptides are 
themselves displayed on the outer surface of the phage at the tips by genetic 
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fusion to minor coat proteins (e.g., p3 display) or along the length by genetic 
fusion to major coat protein p8 (p8 display). Thus, a library made of billions of 
phage clones with each clone displaying a unique foreign peptide sequence can 
be constructed.342 Currently, there are two major types of peptide libraries: (1) a 
p3-displayed phage library where each peptide is displayed at the p3 tip through 
fusion to 5 copies of p3, and (2) a p8-displayed phage library where each peptide 
is displayed along the side wall through fusion to every copy of p8. The p3-
displayed phage library has been used to identify a peptide sequence that can 
specifically recognize and bind to a target (e.g., a protein344, a cell345, or a 
crystal346) through biopanning. In this chapter, I will use the widely used p3-
displayed phage library346-347 as a pool of peptide candidates to screen the 
peptides that can target and bind the extracellular domain of bone morphogenic 
protein (BMP) receptors (BMPR1A and BMPR2). 
2.1.2 Development of BMP-mimicking peptides.  
BMPs belong to the transforming growth factor-beta superfamily and were 
discovered in bone extracellular matrix (ECM). Among different BMPs, BMP-2 
was found to be able to induce osteogenic differentiation of stem cells337 and 
promote the formation and regeneration of bone.338 BMP-2 forms dimers, which 
function by binding to type I and type II bone morphogenic protein receptors on 
the cell surface to initiate osteogenic differentiation. Although the precise 
receptor-binding region in BMP-2 is still unknown, there has been some general 
understanding of the role of BMP-2 in osteogenic differentiation of cells. BMP-2 
signals go through heteromeric complexes of transmembrane Serine/Threonine 
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kinase receptors339: BMPR1A and BMPR2,332-336 which then propagate signals 
to the Smad pathway. Binding of BMP-2 to its receptor complex results in the 
phosphorylation of R-Smads (Receptor-Regulated Smads): Smad1, Smad5 and 
Smad8 molecules. Once phosphorylated, R-Smads dissociate from the receptor, 
form a complex with the Co-Smad called Smad4, and enter the nucleus to 
activate the transcription of specific genes involved in the osteoblast 
differentiation.340 There have been limited studies on the effect of domains of 
BMP-2 on osteogenic differentiation, and some domains were found to promote 
osteogenic differentiation.338, 348 For example, the sequence corresponding to the 
domain (residues 73-92) of the BMP-2, KIPKASSVPTELSAISTLYL, can bind to 
a BMP-2-specific receptor, and elevate both alkaline phosphatase (ALP) activity 
and osteocalcin (OCN) mRNA in the murine mesenchymal cell line.338 However, 
the reported work used either free synthetic peptides or peptides chemically 
immobilized on a material surface, which does not allow for an easy systematic 
study of the stem cell fate in response to single or dual peptides on the same 
surface. Moreover, the reported work does not recognize that two peptides, 
derived from BMPR1A- and BMPR2-binding domains from BMP-2, respectively, 
may act together to induce or promote the osteogenic differentiation. In addition, 
BMP-2 is an expensive growth factor. Thus, there is a need to identify one or two 
short peptide sequences derived from BMP-2 that can induce or promote the 
osteogenic differentiation. Phage display can identify BMPR1A and BMPR2 
binding peptide domains. Namely, BMPs bind and recognize BMP receptors 
(BMPR1A and BMPR2) to trigger the osteogenic differentiation. Hence, BMP 
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receptor-binding peptides may potentially mimic BMPs in inducing osteogenic 
differentiation. Short peptides possess several advantages in biomedical 
applications compared to proteins.324-330 Peptides can be easily synthesized in 
high yields, high purities, and at low costs. Compared to proteins, small molecular 
weight peptides (~2000 Da) can enter cells and penetrate tissue efficiently and 
have a lower immunogenicity.330 Peptides also do not need to be produced in 
animals overcoming burdensome manufacturing conditions as well as ethical 
issues.329-330 Therefore, in this chapter, I utilized phage display techniques to 




Figure 7. Summary of overall research plan. (A) Peptides capable of binding the 
receptors BMPR1A and BMPR2 were selected through biopanning. (Chapter 2) 
(B) Osteogenic peptides were genetically displayed on M13 phage and 
incorporated into phage films for the differentiation of hMSCs into osteoblasts. 
(Chapter 3 and 4) (C) Freeze casting was used to coat 3D printed titanium 
implants with lamellar engineered phage fibers triggering both biophysical and 
biochemical cues for bone regeneration. (Chapter 5) (D) A rat radial bone defect 
model was completed to study bone regeneration using the phage-titanium hybrid 
scaffolds. (Chapter 5) 
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2.2 Materials and Experiments 
2.2.1 Materials 
 Agarose, Anti-M13 Bacteriophage Coat Protein g8p antibody [RL-ph2] 
(ab9225 from Abcam), azino-bis(3-ethylbenzothiazole sulfonic acid) 
diammonium salt (Sigma, cat. # A-1888) ,BMPR1A-Fc (G&P Biosciences), 
BMPR2-Fc (G&P Biosciences), Bovine Serum Albumin,5-Bromo-4- chloro-3-
indolyl-β-D-galactoside (Xgal), Corning® BioCoat™ Poly-D-Lysine Multiwell and 
Assay Plates (Thomas Scientific), dimethyl formamide,E. coli host strain 
ER2738 (New England Biolabs), Glycine-HCl, Goat-anti mouse AF-488 
(Abcam), isopropyl-β-D-thiogalactoside (IPTG), Ethanol (Sigma-Aldrich), 
Human Mesenchymal Stem Cells (Lonza),Luria Broth Medium,Mesenchymal 
stem cell growth mediaBulletKit (PT-3238 & PT-4105) (Lonza),mouse anti-g3p 
(p8) IgG, Ph.D.™-12 Phage Display Peptide Library Kit (New England Biolabs), 
phosphate buffered saline,polyethylene glycol–8000 (PEG), PureBlu™ Hoechst 
33342 Nuclear Staining Dye #1351304 (BioRad), Sodium Azide, Sodium 
Bicarbonate,Sodium Chloride, Tetracycline, 3,3',5,5'-Tetramethylbenzidine, Tris-
HCl. 
2.2.2 Negative selection of plastic binders 
The Ph.D.™-12 phage library (New England Biolabs) was diluted in tris-
buffered saline mixed with Tween-20 (TBS + 0.1% v/v Tween-20 and 
abbreviated TBST) for a final concentration of 2 x 1011 phage in 1 mL of TBST. 
The diluted library was then pipetted onto one of the wells of a 12-well poly-L-
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lysine plate followed by rocking the plate gently for 60 minutes at room 
temperature. Next, the supernatant containing phages which did not bind to 
either the plate or poly-L-lysine were collected. This supernatant served as the 
starting phage library for subsequent binding selections. The phages which 
stuck to the plate were discarded. 
2.2.3 Immobilization of target 
This procedure is only applicable if the charge of the desired protein to 
be immobilized is negative. Check the isoelectric point (pI) value for your 
protein before proceeding. When the pH > pI, a protein has a net negative 
charge. This procedure was written for 12-well plates coated in poly-L-lysine 
(positively charged). Adjust volumes appropriately if you are using a different 
size plate. Separate solutions of pI=5.72 BMPR1A-Fc (G&P Biosciences) and 
pI=5.90 BMPR2-Fc (G&P Biosciences) were prepared at 80 µg/mL in Tris-
buffered saline (pH 7.5). In separate wells and on separate poly-L-lysine coated 
12-well plates, 0.3 mL of each solution of receptor was added. The solutions of 
BMPR1A-Fc and BMPR2-Fc were swirled around the plate surface until the 
entire surface was wet. The plates were then incubated overnight at 4 degrees 
Celsius with gentle agitation in a humidified container (a sealed plastic box with 
damp paper towels). Each individual receptor was now immobilized.  
2.2.4 Selection procedure 
The following selection procedure is based off of the direct coating 
procedure outlined in the Ph.D.™-12 Phage Display Libraries instructional 
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manual (New England Biolabs) with some alterations. This procedure was 
carried out after immobilizing the targets BMPR1A-Fc and BMPR2-Fc in a 12-
well poly-L-lysine coated plate. A stock solution of tetracycline was prepared 
(20 mg / ml in 1:1 ethanol:water). The coating solution containing the target 
receptors was poured off followed by firmly slapping the plates face down on a 
clean paper towel. Each well was then filled with blocking buffer (0.1 M NaHCO3 
(pH 8.6), 5 mg / mL BSA, 0.02% NaN3. Filter sterilize, store at 4°C) and 
incubated for 1 hour at 4°C. The blocking solution was then poured off followed 
by firmly slapping the plates down against a clean paper towel. Each plate was 
washed rapidly 6 times with Tris-buffered saline mixed with Tween-20 (TBS + 
0.1% v/v Tween-20). The plate was slapped against a clean paper towel each 
time. 1 mL of the phage library created from the negative selection process was 
then pipetted onto each of the target coated wells. The plates were then rocked 
gently at room temperature for 60 minutes. The non-binding phages were then 
discarded by pouring off the supernatant and slapping the plate face-down on a 
clean paper towel. The plate was then washed 10 times with TBST followed by 
slapping the plate face-down on a clean paper towel each time (a clean section 
of paper towel was used each time to prevent cross-contamination). The bound 
phages were then eluted by incubating with a nonspecific disruption buffer (0.2 
M Glycine-HCl (pH 2.2), 1 mg/ mL bovine serum albumin (BSA) for 15 minutes. 
The eluate (immersed in the disruption buffer) was then pipetted into a 
microcentrifuge tube followed by neutralization with 150 µL of 1 M Tris-HCl (pH 
9.1). A small portion (~1 µL) of this eluate could be titered and sequenced if 
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desired (see titering section). The rest of the eluate was amplified (see 
amplification of phage library section). Once amplified, the eluate was also 
tittered to determine the concentration of amplified phages by counting the blue 
plaques in titering (as described below). The amplified library was diluted to 
contain 2x1011 phages in 1 mL of TBS (as little as 109 plaque forming units per 
mL can be used). A second poly-L-lysine 12-well plate was then coated with the 
target receptors to allow for a second round of biopanning. A second round of 
biopanning was carried out doing the same steps except that the Tween-20 
concentration in the wash steps was raised to 0.5% (v/v). The eluate from the 
second round was then amplified, titered and used in an additional 3rd round of 
panning on newly receptor coated plates. 0.5% Tween was again used in the 
washing steps for the 3rd round. After the 3rd round of panning, the eluate was 
titered. Blue plaques from the titering were picked and incubated in 10 mL of 
luria broth overnight. The cultures were then mixed with an equal amount of 
50% glycerol in water and stored at -80°C or sent on ice for sequencing.  
2.2.5 Titering 
The E. coli strain ER2738 was inoculated into 10 mL of luria broth and 
tetracycline (final concentration of 12 µg/mL tetracycline). The phages contain a 
gene which provides E. coli resistance to tetracycline when infected. The 
culture was incubated at 37 °C with vigorous shaking. This culture was grown to 
an early log phase of growth (optical density at 600 nm was between 0.01-
0.05). The top agar was melted in the microwave and 3 mL was transferred to a 
sterile culture tube. One of these tubes was prepared for each corresponding 
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phage dilution. The phage dilutions of the amplified panning eluate were 
typically from 108-1010 pfu and they were 101-104 pfu for unamplified eluate. The 
early log phase E. coli culture was then dispensed into separate 200 µL 
microcentrifuge tubes (one for each phage dilution). The cultures were then 
inoculated with 10 µL of phage solution for each individual dilution. The 
inoculated culture was allowed to incubate at room temperature for 1-5 minutes. 
The infected cells were then transferred one infection at a time to the culture 
tubes containing 45°C Top Agar. The tubes were vortexed briefly and 
immediately poured onto prewarmed LB/IPTG/Xgal plates prepared according 
to the Ph.D.™-12 Phage Display Libraries instructional manual (New England 
Biolabs). The plates were gently tilted to pread the top agar out evenly. The 
plates were then allowed to cool for 5 minutes at room temperature, inverted, 
and incubated overnight at 37°C. On the next day, the blue plaques could be 
counted or picked for sequencing. For plates that had roughly 100 plaques, the 
plaques were counted and the number of plaques was multiplied by the dilution 
factor to get the plaque forming units per 10 µL.  
2.2.6 Amplification of phage library 
The E. coli strain ER2738 was inoculated into 20 mL of luria broth 
medium in a 250 mL Erlenmeyer flask. The culture was incubated at 37 °C with 
vigorous shaking. The eluate not used for titering from the previous round of 
selection (depending on which round was last completed) was added to the 20 
mL ER2738 culture during the early-log phase of growth (optical density at 600 
nm was between 0.01-0.05). The culture was then incubated for 4.5 hours at 
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37°C with vigorous shaking. The culture was then transferred to a centrifuge 
tube and spun for 10 minutes at 12,000 g at a temperature of 4°C. The 
supernatant was then transferred to a new tube and re-spun. The upper 80% of 
the supernatant was then transferred to a new tube and mixed with 1/6 volume 
20% PEG/2.5 M NaCl. The phages were then allowed to precipitate out at 4°C 
overnight (or a minimum of 2 hours). The PEG precipitated phages were then 
centrifuged at 12,000 g for 15 minutes at 4°C. The supernatant was discarded 
and the tube was re-spun briefly. Any residual supernatant was removed with a 
pipette. The phage pellet was then visible as a very small white finger print like 
smear on the side of the tube. The pellet was then resuspended in 1 mL of 
TBS. The resuspended phages were then centrifuged at 14,000 rmp for 5 
minutes at 4°C to remove any residual cells. The supernatant was then 
transferred to a new microcentrifuge tube followed by reprecipitation in 1/6 
volume 20% PEG/2.5 M NaCl. The solution was incubated on ice for 60 
minutes. The solution was then microcentrifuged on a table top centrifuge at 
14,000 rpm for 10 minutes at 4°C. The supernatant was again discarded, and 
the tube was spun briefly followed by removal of any additional supernatant. 
The pellet was then resuspended in 200 µL of TBS. The phage solution was 
then re-spun for 1 minute to remove any insoluble material. The supernatant 
was transferred to a fresh tube. This solution was considered the amplified 
eluate. 
2.2.7 DNA sequencing to determine peptides  
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Blue plaques from the titering were picked and incubated in 10 mL of 
luria broth overnight. The cultures were then mixed with an equal amount of 
50% glycerol in water and stored at -80°C or sent on ice for sequencing. Those 
samples sent for sequencing were sent to MCLAB Molecular Cloning 
Laboratories. The pIII coat protein gene for M13 phage was sequenced. The 
resulting chromatogram files containing the sequencing data were analyzed 
using FinchTV software. The peptide sequences could be determined according 
to the Ph.D.™-12 Phage Display Libraries instructional manual (New England 
Biolabs). An example of processing the data is shown in Table 6. 
2.2.8 Enzyme-linked immune sorbent assay for receptor binding 
A blocking buffer (0.1 M NaHCO3 (pH 8.6), 5 mg/mL BSA, filter sterilized, 
and stored at 4°C) was prepared. TBS (50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, autoclaved, stored at room temperature) was prepared. Separate 
solutions of the target receptors were then made. For BMPR1A, a 10 
µg/mLstock solution was made. For BMPR2, a 10 µg/mL solution was also 
made. Four separate wells for each different peptide bearing phage group 
(which will be added after the wells are coated in receptors) were then coated 
with one of the receptors. The coating was done by adding 100 µL of the 
BMPR1A or BMPR2 solutions to wells of a 96-well plate followed by swirling 
until the surface was completely wet. The plates were then allowed to incubate 
overnight at 4 °C with gentle agitation in a humidified container (a plastic box 
lined with damp paper towels). Any excess target solution was then removed, 
and the plate was slapped face-down on a clean paper towel. The wells of the 
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plate were then blocked with 200 µL of blocking buffer for 1 hour at room 
temperature. An additional row of uncoated wells was also blocked to serve as 
a background signal control. The blocking buffer was then removed from each 
plate followed by 5 washes with 200 µL of TBST. Each time the plate was 
slapped against a clean section of paper towel face-down. In a separately 
prepared blocked plate, serial dilutions of the phages in 200 µL of TBST were 
prepared. After a brief pilot test, it should be noted that using 1010 phage / mL 
was determined to work best (lowest concentration needed to still differentiate 
between conditions), but other higher concentrations of virus also worked 
consistently. Therefore, 100 µL of 1010 phage / mL was pipetted (with a 
multichannel pipettor) to each row of target-coated wells as well as the rows 
without target. The mixtures were incubated at room temperature for 1.5 hours 
with agitation. The wells were then emptied and washed 5 times with 200 µL of 
TBST. Next, 100 µL of mouse anti-g3p (p8) IgG was added to every well 
followed by incubation at room temperature for 1 hour. The wells were then 
washed 5 times with 200 µL of TBST. Then, 100 μL of anti-mouse IgG 
conjugated with HRP (diluted in TBST + 5% BSA) was added to every well 
followed by incubation for 1 hour. The wells were emptied followed by 5 more 
washes with 200 μL of TBST. Then, 100 μL of freshly prepared 3,3',5,5'-
Tetramethylbenzidine (TMB) was added to each well and the absorbance at 
370 nm and 652 nm was monitored for 1 hour using an ELISA plate reader. 
After 1 hour, the substrate reaction was stopped using equal volumes (100 μL) 




2.2.9 Live cell binding through immunofluorescence 
 Human mesenchymal stem cells (hMSCs) were grown to roughly 60% 
confluence in a 48-well tissue culture plate according to the company Lonza’s 
culturing protocols. Phages (each type having a different peptide displayed on 
the pIII coat protein which were previously isolated through biopanning) were 
then filtered (0.2 µm syringe filter) and subjected to 1 hour of ultraviolet (UV) 
light for disinfection. The hMSCs were then blocked with 0.5% BSA (dissolved 
in cell media) for 1 hour. The cell media for the hMSCs was then replaced with 
1 mL of new cell media having of concentration of 1012 phages / mL followed by 
incubation for 6 hours at 37 degrees Celsius. Next, the plates were washed 
once with 400 µL of phosphate buffered saline (PBS) at a pH of 7.4. The 
hMSCs were then incubated with Anti-M13 Bacteriophage Coat Protein g8p 
antibody [RL-ph2] (ab9225) at a 1:1000 dilution in cell media (200 µL per well). 
The wells were then washed again with PBS (400 µL per wash). Next, the 
hMSCs were incubated with the fluorescent secondary antibody, Goat-anti 
mouse AF-488 (Abcam) for 1 hour (1 ug/mL final concentration of antibody in 
media). The wells were then washed again with PBS (400 µL per wash). A 
Hoechst nuclear stain was used to stain the nuclei (PureBlu™ Hoechst 
33342 Nuclear Staining Dye #1351304 from BioRad) according to the 
company’s protocol. Cell MaskTM Orange Plasma Membrane Stain was used to 
stain membranes (CellMask™ Orange Plasma Membrane Stain Catalog 
number: C10045 from Thermo Fisher Scientific) according to the company’s 
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protocol. The phages binding to the cells were then imaged on a Nikon Eclipse 
Ti fluorescent microscope.  
2.3 Results and Discussion 
2.3.1 Sequencing results and frequency of peptides 
 Upon sequencing the phages which remained after biopanning on the 
receptors BMPR1A and BMPR2, the DNA sequences were converted into 
peptide sequences for the peptide insert region of the DNA. The resulting 
frequencies and sequences are shown in Figure 8. Each tick mark on the 
frequency axis represents a plaque picked from biopanning which was 
sequenced. For the receptor BMPR1A, the most frequently obtained peptide 
was TAKYLPMRPGPL followed by other promising peptides. For the receptor 
BMPR2, RDYHPRDHTATW was the most frequent peptide. While a higher 
frequency may indicate better binding to the receptors, it can also represent a 
preference in the ability of a phage to replicate during the amplification steps. 
Therefore, frequency alone is not a reliable indicator of the best peptides to 
select. Knowing this, both the highest frequency peptides and peptides which 
showed more unique sequences were selected for further tests. The 
sequencing results of those peptides later shown to have more promise are 




Figure 8. Frequency of peptide sequencing results from biopanning on (a) 
BMPR1A and (b) BMPR2. This figure shows the diversity of peptide sequences 
obtained through biopanning as well as the highest frequency peptides. 
Table 6. The DNA FASTA sequences corresponding to peptides obtained 
through biopanning on BMPR1A. For those peptides with multiple frequencies 
of occurring only one example is shown. Only sequences later found to be 
relevant for bone regeneration are shown. 
Peptide FASTA DNA Sequence for M13 phage pIII coat protein 
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Table 7. The DNA FASTA sequences corresponding to peptides obtained 
through biopanning on BMPR2. For those peptides with multiple frequencies 
of occurring only one example is shown. Only sequences later found to be 
relevant for bone regeneration are shown. 
Peptide FASTA DNA Sequence for M13 phage pIII coat protein 



























(Appears in both 
biopanning targets) 






























2.3.2 Relic peptide analysis 
 Bone morphogenic protein 2 (BMP-2) is a popular and potent osteoblast 
inducer which naturally binds to the receptors BMPR1A and BMPR2. Due to the 
strategy of biopanning, it was expected that some peptides may resemble 
sequences in BMP-2. To test this option, the sequences were loaded into a 
program called RELIC. RELIC uses a scoring matrix to test similarity scores 
between peptide sequences. Typically, a score above 10 indicates a region of 
similarity.344 Out of all of the peptides, the peptide SGTQDSMVGWNK 
demonstrated significant similarity to a region of BMP-2, LYVDFSDVGWND. 
This similarity may indicate that this region of BMP-2 has some yet unknown 
role in receptor binding or activation. The results of the RELIC analysis are 






Figure 9. The peptides discovered through biopanning were compared to 
BMP2 at each amino acid position (a) using a bioinformatics program 
(RELIC/MATCH). (a-b) Similarity scores (a) and alignment (b) of the peptide 
SGTQDSMVGWNK to BMP2 demonstrated a high degree of similarity between 
the peptide SGTQDSMVGWNK and a region of BMP2. In (b), the peptide was 
aligned under the full sequence of BMP2. 
2.3.3 Relative binding strengths of selected peptides and live cell binding 
of peptides to hMSCs 
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 The peptides selected to be tested for relative binding strength in an 
ELISA are shown in Figure 10a and 10b. For the receptor BMPR1A, 3 
statistically significant peptides emerged as the best binders. These peptides 
were VHVPLHRGAVSA, SGTQDSMVGWNK, and TAKYLPMRPGPL. For the 
receptor BMPR2, the sequences RDYHPRDHTATW and SGTQDSMVGWNK 
were statistically significant binders. The peptide SGTQDSMVGWNK was 
especially interesting because it showed up as a result of biopanning on both 
BMPR1A alone and BMPR2 alone. Additionally, live hMSC interactions with 
peptide-bearing phages were observed through immunofluorescence. Figure 
10c shows that the phages (shown in green) for the sequences 
SGTQDSMVGWNK, RDYHPRDHTATW, and VHVPLHRGAVSA bind to what 
appears to be the same location as the outer membrane. The receptors are 
transmembrane receptors, and therefore it was expected that the binding would 
occur on the outer membrane as was observed. It is also not expected that the 
phages enter hMSCs because of their biology, so they are likely on the surface 




Figure 10. Evaluation of the BMPR-binding peptides in binding BMPRs. (a and 
b) Comparative ELISA test for binding of peptides to BMPR1A (a) and BMPR2 
(b). The ELISA (n=4) was carried out using a phage concentration of 2x1012 
phage/mL. The phage displayed the peptide indicated on its p3 coat protein. The 
primary antibody was mouse anti-g3p (p8) IgG. The secondary antibody was anti-
mouse IgG conjugated with horseradish peroxidase (HRP). The substrate of the 
HRP, 3,3',5,5'-Tetramethylbenzidine, was detected at 450 nm after stopping the 
reaction with 1 M HCl. The data shows that the peptides VHVPLHRGAVSA, 
SGTQDSMVGWNK, TAKYLPMRPGPL, and RDYHPRDHTATW all bind the 
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receptors significantly better than wild type. (c) Fluorescence images of the 
peptides (displayed on p3 of phage) binding live hMSCs. In green, Primary: 
Mouse anti-g3p (p8) IgG; Secondary: Goat-anti mouse AF-488: IgG H and L. In 
red, Cell MaskTM Orange Plasma Membrane Stain. Orange, overlay of red and 
green. The 4 best peptides determined by ELISA in (a) and (b), including 2 
MPRR1A-binding peptides and 2 BMPR2-binding peptides, were chosen as 
indicated. Among these 4 peptides, the peptides SGTQDSMVGWNK, 
RDYHPRDHTATW, and VHVPLHRGAVSA showed the best binding images. All 
data represent the mean + standard deviation (n=4, *, **, ***, and **** represent 
a P value not higher than 0.05, 0.01, 0.001, and 0.0001, respectively). This data 
shows that the peptides selected preferentially bind to their respective receptors. 
2.4 Conclusion 
 In this chapter, I used a technique called biopanning to isolate M13 
phages bearing peptides capable of binding to the receptors BMPR1A and 
BMPR2. These peptide-bearing phages were demonstrated to bind significantly 
better than a wild type phage control in ELISA tests. The peptides 
SGTQDSMVGWNK, RDYHPRDHTATW, and VHVPLHRGAVSA also 
demonstrated an ability to bind to some locations on the outer membrane 
(presumably on the BMPR1A and BMPR2 receptors) of live hMSCs. 
Additionally, a peptide matching and scoring system, RELIC identified that the 
peptide SGTQDSMVGWNK shows a high similarity with a previously 
uncharacterized region of BMP-2.  
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Chapter 3: Generating a genetically engineered virus displaying 
newly discovered differentiation peptides and assembling it 
into a precise nanostructured film to control stem cell 
differentiation into osteoblasts 
3.1 Introduction 
 In the previous chapter, possible bone regenerative peptides were 
discovered. In this chapter, I will focus on techniques which were used to 
evaluate the ability of these peptides.  
3.1.1 Genetic manipulation of M13 phages 
Filamentous temperate M13 phages can be pictured as a long flexible 
nanofiber composed of five structural capsid proteins, which encase a relatively 
large circular single strand of DNA.23, 92 Wild-type M13 phage measures ~9300 
Å long, but has a diameter of only 65 Å.20 The M13 virion consists of ~6407 
bases of circular single-stranded DNA (ssDNA) in its genome, but longer 
genomes generate longer phages.20-22 Although there are five different proteins, 
the majority of a filamentous phage is coated by ~2700 copies of a protein 
encoded by a single gene called pVIII,23 which is helically arranged to form a 
filament tube.92 This is the protein that is often modified for desirable 
characteristics and will be genetically modified in this work to provide more 
copies of the peptides selected in the previous chapter. The ends of filamentous 
phages are composed of minor coat proteins. One end is composed of five 
copies of the proteins pIII and pVI, while the opposite end displays five copies 
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of the proteins pVII and pIX.22-24 The filamentous structure and major coat 
proteins are what makes these phages capable of creating many self-
assembled nanostructures as well as develop excellent targeting abilities. By 
inserting DNA encoding peptides into the genes of the coat proteins, the 
peptides are themselves displayed on the outer surface of the phages at the 
tips by genetic fusion to minor coat proteins (e.g., pIII display) or along the 
length by genetic fusion to major coat protein pVIII (pVIII display). 
 
3.1.2 Phage films 
M13 bacteriophages have been implemented in a variety of organic 
synthesis strategies and organic biomaterials.349-350 One of the major 
biomaterials made out of M13 phages is called phage film.68, 351 Phage films 
consist of self-assembled layers of M13 phages that can come in a variety of 
nanotopographies depending on the preparation method.8, 10, 352-355 Often times, 
the phages are naturally self-assembled into a ridge groove structure with the 
help of a pulling force.8 However, due to the liquid crystalline properties of M13 
bacteriophage, even more complex structures can be made.10 A major benefit 
of phage films is that different peptides can be displayed on the phages without 
changing the structure of the film.8 This allows for distinguishing the effects of 
different peptides in cellular differentiation assays.8 
3.1.3 Osteoblast markers 
 Osteoblasts are essential for new bone formation. Osteoblasts are 
responsible for the synthesis and secretion of the majority of the proteins in the 
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bone extracellular matrix.356 Osteoblast also induce mineralization of the 
extracellular matrix. Osteoblasts are derived from undifferentiated 
mesenchymal stem cells. These mesenchymal stem cells have the capacity to 
differentiate into osteoblasts, adipocytes, chondrocytes, and myoblasts.356-
357There are several frequently used markers for identifying osteoblasts. Some 
common markers include alkaline phosphatase, type I collagen, osteopontin, 
bone sialoprotein, and osteocalcin.356 However, the expression of these 
markers can vary over time. For example, alkaline phosphatase, bone 
sialoprotein, and collagen type 1a can be early indicators of osteoblast 
differentiation while osteocalcin is a late marker.356Osteopontin expression 
peaks twice during proliferation and can later peak again during the late stages 
of differentiation.356 None of the genes mentioned which are involved in the 
extra cellular matrix mineralization are unique to osteoblasts or bone.356 
However, the coexpression of these genes is unique to 
osteoblasts.356Therefore, several of these markers and calcium mineralization 
were the focus of establishing osteoblast differentiation in this chapter. 
3.2 Materials and Experiments 
3.2.1 Materials 
Acetic acid, agarose, alamarBlue® (Bio-Rad), Calcium Chloride, 
Chloramphenicol, deoxynucleosidetriphosphate, E. coli strain TG1, ER2738 
bacteria (New England Biolabs), Ethylenediaminetetraacetic acid (EDTA), 5 × 
GC buffer, Glycerol,Goat Anti-Rabbit IgG H&L Alexa Fluor 555ab150078 
(Abcam),Goat Anti-Mouse IgG H&L (Dylight 650) preadsorbed ab96882 
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(Abcam), hMSC Osteogenic BulletKit (Lonza),Hind III restriction enzyme (New 
England Biolabs),human collagen type 1A primer (GeneCopoeia), human 
GAPDH primer (GeneCopoeia), human osteocalcin primer (GeneCopoeia), 
human osteopontin primer (GeneCopoeia), Luria broth, M13KO7 phage (New 
England Biolabs), Mesenchymal stem cell growth medium BulletKit (Lonza), 
MiniOpticon Real Time PCR System (Bio-Rad), Nco I restriction enzyme (New 
England Biolabs),OCN [OC4-30] ab13418 (Abcam), Pfu 1U DNA polymerase, 
polyethylene glycol–8000,Power SYBR™ Green Cells-to-CT™ Kit (Thermo 
Fisher Scientific), QIAgen gel DNA extraction kit, QIAgen miniprep plasmid 
extraction kit, RbpAB to osteopontin ab8448 (Abcam),T4 ligase (Invitrogen), 
Tris base , XL_1 Blue E. Coli harboring the PeCan49 phagemid DNA for 
chloramphenicol resistance, uranyl acetate. 
3.2.2 M13 Phage Display 
Peptide: VHVPLHRGAVSA 
Forward Primer (Primer 1 differs for each peptide) Nco 1 restriction 
site 
5’-ATCCATGGCGGTTCATGTTCCGTTGCATAGGGGTGCGGTTTCGGCGGATCCCGCAAAAGCG-3’ 













Forward Primer (Primer 1 differs for each peptide) Nco 1 restriction 
site 
5’-ATCCATGGCGCGGGATTATCATCCTCGTGATCATACTGCTACTTGGGATCCCGCAAAAGCG-3’ 




Forward Primer (Primer 1 differing for each peptide) Nco 1 
restriction site 
5’-ATCCATGGCGACTGCGAAGTATCTGCCTATGCGTCCTGGGCCGCTTGATCCCGCAAAAGCG-3’ 









Table 8. The peptide sequences, the peptide structures, the primers used to 
display the peptides on pVIII of M13 phage, the restriction sites for the primers, 
and the net charge of each peptide. 
3.2.2.1 Preparation of M13 plasmid vector 
 A culture of XL_1 Blue E. coli harboring the PeCan49 phagemid DNA 
with chloramphenicol resistance was incubated at 37°C overnight on a LB plate 
(35 μg / ml chloramphenicol antibiotics). A well separated clone from the 
overnight culture was then inoculated into 3 mL of LB medium with the antibiotic 
chloramphenicol and incubated overnight at 250 rmp at 37°C. Phagemid DNA 
was then isolated and prepared with a QIAgen miniprep plasmid extraction kit, 
and the DNA was eluted with 50 μL of sterile double distilled water (ddH2O) 
 Linear vector fragments were prepared by digesting the phagemid DNA 
from the separated clones with both the Nco I and Hind III restriction enzymes 
purchased from New England Biolabs. To accomplish this, a sterile micro-
centrifuge tube had the following components: Phagemid DNA (5 μL), 10× New 
England Biolab buffer 2 (2 μL), Nco I 10 U (1 μL), Hind III 10 U (1 μL), and 
ddH2O 11 μL for a total of 20 μL of solution. The contents of the micro-
centrifuge tube were then incubated for 2.5 hours at 37 °C. 
 After the digestion, the linear fragments were loaded into 1% agarose gel 
and isolated by electrophoresis in 1xTAE buffer (a mixture of Tris base, acetic 
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acid and EDTA). The linear DNA fragments were extracted from the agarose 
gel using a QIAgen gel DNA extraction kit. The DNA was then eluted with 20 μL 
of sterile ddH2O and kept at -20 °C. 
3.2.2.2 PCR reaction (Preparation of insert fragments) 
 The polymerase chain reaction (PCR) was carried out in a sterile 200 μL 
micro-centrifuge tube using a Bio-RAD MJ MiniTM Personal Thermal Cycler. 
See Table 9 for primers. The reaction system consisted of M13KO7 phage RF 
DNA (2 μL) as the DNA template, primer 1 (1 μL at 50 pmol), primer 2 (1 μL at 
50 pmol), 10 mM deoxynucleoside triphosphate (dNTP)(1 μL), 5 × GC buffer 
(10 μL), ddH2O (35 μL), and Pfu 1U DNA polymerase (0.5 μL) under the PCR 
cycling conditions of 98 °C for 30 sec, 30 cycles (98 °C for 10 sec, 56 °C for 30 
sec and 72 °C for 15 sec), and a last extension at 72 °C for 4 minutes. This 
process is outlined in Figure 11. 
3.2.2.3 PCR products purification and digestion 
 PCR products were purified using a QIAgen PCR product purification kit. 
The DNA was eluted with 10 μL of sterile ddH2O. The purified DNA was then 
digested with both the Nco I and Hind III restriction enzymes in a sterile micro-
centrifuge tube. Next, the micro-centrifuge tube was incubated for 2.5 hours at 
37°C. After this digestion, the DNA fragments were loaded into 1% agarose gel 
and isolated by electrophoresis in 1 x TAE buffer. The digested fragment of 
DNA was removed from the agarose gel by gel extraction. The DNA was then 
eluted with 20 μL of sterile ddH2O. 
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3.2.2.4 Preparation of TG1 competent cells 
 An overnight culture of E. coli strain TG1 was grown in a 125 mL sterile 
flask containing LB at 37 °C with vigorous shaking to an optical density of ~0.4 
at 600 nm. The cells were then collected by centrifuging at 2500 rmp at a 
temperature of 4°C for 10 minutes. The cells were then re-suspended in 10 mL 
of cold sterile 100 mM CaCl2. Next, the cells were kept on ice for 30 minutes 
and then collected by centrifuging. Cells were resuspended in 100 mL of CaCl2 
containing 15% glycerol. The competent cells were then stored at -80 °C until 
needed. 
3.2.2.5 Ligation reaction 
 The ligation reaction was carried out by mixing the DNA vector fragment 
(phagemid) (0.020 pmol), insertion fragment from the PCR (0.060 pmol), 5 x 
ligation buffer (4 μL), T4 ligase from Invitrogen (2 μL), and ddH2O (8 μL). The 
reaction was incubated at 25 °C for 2 hours. This process is outlined in Figure 
12. 
3.2.2.6 Transfection of DNA into competent E. coli TG1 cells (CaCl2 
method) 
 In a sterile 1.5 mL Eppendorf tube, 100 μL of competent cells and 20 μL 
of ligation mixture was mixed. The mixture was held in ice water for 1 hour, 90 
seconds at 42 °C, and then 2 minutes in ice water. Luria broth medium (1 mL) 
was added to the tube followed by incubation at 37 ºC for 1 hour in a shaking 
incubator. The transfected bacteria (200 μL) was then transferred onto a luria 
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broth plate containing chloramphenicol. The vector fragments without ligation 




Figure 11. Generation of the insertion fragment for phage display. 
This example is for the peptide VHVPLHRGAVSA. (A) Primer 1 
and primer 2 are digested with the restriction enzymes Nco I and 
Hind III respectively. T(B) The resulting sticky ends generated by 
the restriction enzymes. (C) PCR reaction and alignment of sticky 
ends to M13KO7 phage RF DNA. This process can create several 
options for products. (D) The desired end product is shown. This 
will be the only product which has both necessary restriction sites. 
These restriction sites get used later to generate new sticky ends 





Figure 12. Insertion of M13KO7 phage RF DNA into the PeCan49 phagemid 
display vector. The final products from the PCR reactions on the M13KO7 RF 
DNA as well as the PeCan49 Phagemid Display Vector were cut by Nco I and 
Hind III to generate sticky ends. These sticky ends interact to insert the 
modified M13KO7 phage RF DNA harboring the sequence for the desired 
peptides into the PeCan49 Phagemid display vector. A T4 ligase is used to fully 
join the pieces. This leaves a PeCan49 phagemid vector harboring both 
chloramphenicol resistance and the desired gene for displaying peptides on the 
pVIII coat protein of M13 phage. The modified phagemids can then be used to 
transform the competent cells into cells which are both resistant to 
chloramphenicol and produce the desired engineered pVIII coat protein. When 
an M13KO7 helper phage is incubated with the transformed cells, many of the 
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pVIII coat proteins of the new phages will have the engineered pVIII coat 
protein.  
3.2.2.7 Confirmation of recombinant phagemid 
 Individual colonies of bacteria were then inoculated into luria broth 
medium and amplified. The phagemid was purified from the amplified bacteria 
and sent for sequencing (MCLAB) to confirm the insertion fragment was added 
and the sequence did not have mutations. It should be noted that the cell line 
TG1 was very poor for amplifying phages but did harbor the correct plasmid 
sequence. Therefore, this method was repeated using ER2738 competent cells 
(sequenced again) and the amplification of phages was greatly improved.  
3.2.3 Amplification of genetically engineered M13 phage 
ER2738 (with recombinant plasmid) was inoculated into 5 mL of luria 
broth containing chloramphenicol (0.05 mg/mL). The culture was incubated at 
37 °C at 200 rpm overnight.300 uL of overnight culture was mixed with 1200 uL 
of luria broth with 45 uL of helper phage (M13KO7). The mixture was incubated 
without shaking at 37 °C for 1 hour, then transferred to 30 mL of luria broth. The 
mixture was then shaken for 1 hour followed by the addition of 30 uL of 
chloramphenicol additional shaking for 3 more hours. The mixture was then 
transferred to 2.0 L of LB containing kanamycin (0.07 mg/mL) and IPTG (0.1 
mM). The mixture was then incubated for 24 hours at 37 ºC with vigorous 
shaking. The mixture was then centrifuged at 8200 g for 50 minutes. The 
supernatant which contains the isolated phages after amplification was 
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transferred to a new container and mixed with 1/6 volume 20% PEG/2.5 M 
NaCl. The mixture was allowed to precipitate overnight at 4 ºC. Next, the 
mixture was centrifuged at 8200 g for 50 minutes at 4 ºC. The supernatant was 
discarded. The mixture was re-spun briefly followed by the removal of any 
residual supernatant. The pellet of phages was then resuspended in 10 mL of 
distilled water and transferred to a centrifuge tube. The mixture was then 
allowed to disperse more evenly over time by shaking it for 1 hour at room 
temperature (centrifugation can cause aggregation of phages). The mixture was 
then centrifuged at 7200 rpm for 50 minutes to remove any residual bacteria or 
other insoluble material. The supernatant was then transferred to a new tube 
and mixed with 1/6 volume 20% PEG/2.5 M NaCl. The mixture was then 
allowed to precipitate at 4 ºC overnight. Next the precipitated mixture was 
centrifuged at 7200 rpm for 50 minutes. The supernatant was discarded, and 
the pellet was resuspended in 1 mL of distilled water. The solution was 
transferred to a microcentrifuge tube followed by shaking for 1 hour at 200 rpm 
(or until the phage pellet fully dissolved). The solution was then centrifuged at 
12,000 rpm on a table top centrifuge for 10 minutes to remove any insoluble 
material. The supernatant was transferred to a new tube and the optical density 
at 269 nm was measured to determine the concentration based on a 
proportionality concentration curve (optical density x 1x1014 = number of 
phages / mL). This process only works within the linear portion of the calibrated 
concentration curve (from 0.1 to 1.0 optical density). To further purify the 
phages, the phages were then transferred into dialysis tubing. Dialysis was 
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carried out in 5 L of distilled water with water changes every 3 hours for 9 
hours. A final water change was allowed to go overnight. Next, the phages were 
transferred to vortex tubes and vortexed for 1 minute. The phages were then 
passed through a 0.2 µm filter. The concentration could then be re-measured 
using the same optical density procedure.  
3.2.4 Generation of phage films 
 This procedure can be scaled for any size well plates or petri dish, but 
the volumes included are for 96-well tissue culture plates. For each film, 120 µL 
of poly-L-lysine was pipetted into a well of a tissue culture 96-well plate. The 
solution was allowed to incubate at room temperature for 30 minutes. The poly-
L-lysine was pipetted out and saved in a clean container. The plates were 
allowed to completely dry in a sterile cell culture hood with the fan on. 100 µL of 
1.5x1013 phage/mL was added to each well. The phage solution was allowed to 
incubate at room temperature for 30 minutes. The phages were transferred to a 
new clean container and the 96-well plate was dried in the hood again. 100 µL 
of the recycled poly-L-lysine solution was pipetted into each well and allowed to 
incubate at room temperature for 30 minutes. The poly-L-lysine solution was 
discarded, and the wells were allowed to completely dry again in the hood. 80 
µL of the recycled phage solution was pipetted into each well. The coating was 
evenly spread across the wells. The solution was allowed to dry overnight in the 
hood. The films (with film structures verified in Figure 13) were exposed to UV 
light in a clean environment for 24 hours. The films were now complete. The 
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films were then soaked in cell medium overnight. The soaking medium was 
then discarded and new medium was used before seeding any cells. 
3.2.5 Characterization of M13 phage (AFM and TEM) 
 M13 phages were characterized by atomic force microscopy (AFM) on a 
BIOSCOPE catalyst with ScanAsyst AFM (Bruker). The samples were prepared 
by pipetting 40 µL of 3x1012 phages/mL onto a glass slide followed by spin 
drying. The samples were imaged under 4 modes, height, inphase, peak force 
error, and quadrature. 
 For transmission electron microscopy (TEM), 10 µL of 1x1012 phages/mL 
were pipetted onto a formvar-coated TEM grid and allowed to soak for 3 
minutes. The extra liquid was then wicked away from the grid using a piece of 
filter paper. 10 µL of 0.5% uranyl acetate at a pH of 4.5 was then added to the 
grid for 10 seconds. The extra uranyl acetate was then wicked away. The grid 
was then blown dry quickly with a hair dryer. Images were then taken on a 
Zeiss 10 TEM at a magnification of 6300. 
3.2.6 Characterizing phage film morphology 
 Phage films were generated according to the described protocol. The 
phage films were then imaged using a Nikoneclipse Ti microscope under 
brightfield imaging. Additionally, the phage films were imaged using a 
BIOSCOPE catalyst with ScanAsyst AFM (Bruker) under 4 modes, height, 
inphase, peak force error, and quadrature. 
3.2.7 Cell proliferation on phage films 
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hMSCs were seeded onto 96-well plate phage films (200 µL of 1x104 
cells/mL) and grown for 47 hours or 71 hours. Both stimulated and unstimulated 
controls were included. At the end of the indicated growth times, alamarBlue® 
(Bio-Rad) was added as 10% of the volume in the well mixed with cell media. 
The cultures were allowed to incubate 8 hours. The absorbance at 570 nm and 
600 nm were then measured. The percent reduction of alamarBlue® was then 
calculated (higher percent reduction = more growth).  
3.2.8 Immunofluorescence of osteoblast marker proteins 
 After culturing hMSCs on phage films for 26 days, the cells were fixed 
with 4% paraformaldehyde (10 minutes) and permeabilized with 0.2% Triton X-
100 (2 minutes) at room temperature. 5 washes with PBS were done after each 
step. The cells were then blocked with 5% goat serum solution for 1 h followed 
by 5 washes with PBS. The osteogenic protein markers osteopontin (OPN), 
osteocalcin (OCN), and collagen type 1A (COL) were detected through 
immunofluorescence. OPN was detected with the primary antibody for OPN 
(RbpAB to osteopontin ab8448 from Abcam). The secondary antibody used 
was Goat Anti-Rabbit IgG H&L (Alexa Fluor 555) (ab150078) from Abcam 
(red). OCN was detected with the primary antibody for OCN [OC4-30] 
(ab13418) from Abcam). The secondary antibody used was Goat Anti-Mouse 
IgG H&L (Dylight 650) pre-adsorbed from abcam ab96882 (red). COL was 
detected using a primary antibody for COL (RbpAb to collagen 1 ab34710). 
The secondary antibody used was Goat Anti-Rabbit IgG H&L (Alexa Fluor 
555) (ab150078) from abcam (red). Cell nuclei were stained by DAPI (blue) for 
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all samples, and actin was stained by phalloidin (green). The positive control 
was osteogenic media from Lonza ((hMSC Osteogenic Bullet Kit). All other 
samples were grown in basal media (MSCGM Bullet Kit (PT-3238 & PT-4105) 
from Lonza.  
3.2.9 Calcium Nodule Staining 
After 26 days of culturing hMSCs under differentiating conditions, the cell 
media was removed from the 6-well tissue culture plates. The plates were 
rinsed once with PBS. The cells were then fixed with 4% paraformaldehyde 
solution for 10 minutes. After fixation, the wells were rinsed twice with distilled 
water and the cells were stained with 2% Alizarin Red solution (pH 4.2) for 3 
minutes. The wells were then rinsed 5 times with PBS, and the cells were 
imaged using bright field microscopy. 
3.2.10 qPCR of osteoblast marker genes 
 hMSCs were seeded (1x103 cells per culture plate) on to phage films as 
well as relevant control plates. The cells were then cultured for 26 days. The 
cells then were processed with a Power SYBR™ Green Cells-to-CT™ Kit. The 
number of cells was adjusted to be 5x103 cells per lysis reaction. All other 
parameters were kept the same as the manufacturer’s protocol for this kit 
(Thermo Fisher Scientific). The gene expression of osteopontin, osteocalcin, 
and collagen type 1A were measured as a fold change normalized to the 
reference gene GAPDH and a negative control (basal media + cells but no 
phage) such that the baseline at zero-fold change represents the negative 
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control. For temperature cycling and measuring CT values, a MiniOpticon Real 
Time PCR System was used. 
3.3 Results and Discussion 
3.3.1 Sequencing results of phage display 
 On the first sequencing of phage plasmid in TG1 bacteria, the results 
came out with the correct inserts. However, the amplification of engineered 
phages was poor in this strain of bacteria. Generating large quantities of 
phages is essential to use as a biomaterial. Therefore, ER2738 competent cells 
were transfected with the plasmid instead. The sequencing results of this 
transfection are shown in Table 10. All sequences were incorporated as 
desired. 
Table 9. The DNA sequencing results for displaying the indicated peptides on 
the pVIII coat protein of M13 phages. The highlighted region represents the 
inserted DNA sequence which corresponds to the indicated peptide. The 
genetically engineered plasmids are in ER2738 bacteria. 
Peptide FASTA from sequencing corresponding to the pVIII coat 
protein plasmid for M13 bacteriophage (insert highlighted 
in yellow). 













































































































3.3.2 M13 phage morphology images 
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 The amplified M13 phages were imaged by AFM and TEM as shown in 
Figure 13. A single M13 phage measures ~1000 nm in length. A property 
frequently observed with M13 phage is a bundling effect. The bundling effect is 
the tendency for M13 phages to align themselves next to each other and can 
contribute to highly ordered structures as shown.  
 
Figure 13. The morphology of M13 phages. (A) M13 phages imaged by AFM 
on a BIOSCOPE catalyst with Scan Asyst (Brunker). (B) M13 phages imaged 
by a Zeiss 10 transmission electron scope at a magnification of 6300. The 
phages were stained with 0.5% uranyl acetate. 
3.3.3 Organized ridge groove structure of phage films 
 It is well known that M13 phages can self-assemble into ordered 
structures during liquid crystalline phase transitions.353, 358-359 However, the 
consistency of these assembly strategies is far less than desirable as is often 
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the case with M13 phage film structures. Structural differences in films can 
cause differences in cellular differentiation which is problematic when 
comparing different peptides displayed on phages within a phage film. Due to 
repeatability issues, I developed a new protocol as described. This protocol 
involved alternating layers of M13 phages and poly-L-lysine for 2 layers of each. 
A major difference to reported protocols is that the M13 phages were both 
desalted and filtered through a 0.2 µm filter. This provided more clean and 
consistent structures as shown in Figure 14a-c. Also, in the final step the M13 
phage solution was allowed to slowly dry overnight rather than pulling it off 
again. It was also very important to use fresh poly-L-lysine as well as good 
tissue culture plates. The resulting structures are highly organized and more 
repeatable (success 50% of the time on the entire plate, but large regions 
always had this structure even if the whole plate was not uniform). In addition, 
these phage films were highly durable supporting hMSC growth over the course 
of a month with no loss of structure. Additionally, hMSCs grown on these films 
align and stretch with the background structure of organized phages as shown 
in Figure 14b. Due to these properties, these films demonstrated some 






Figure 14. Osteogenic differentiation of hMSCs on phage films. (a-b) Phage 
film ridge groove morphology. Nikon microscope bright field image of 
representative phage film structure without cells (a) and with hMSCs (b). Large 
regions of aligned ridge groove structures can be seen in (a). hMSCs tend to 
bind and stretch along the direction of the phage film grooves (b). (c) Atomic 
force microscopy (AFM) images of the film, further demonstrating an aligned 
fiber-like ridge groove structure. The AFM image was made using the height 
input. (d) Immunofluorescence of osteogenic protein markers including 
osteopontin (OPN), and collagen type 1A (COL). OPN was detected with the 
primary antibody for OPN (RbpAB to osteopontin ab8448 from Abcam). The 
secondary antibody used was Goat Anti-Rabbit IgG H&L (Alexa Fluor 555) 
(ab150078) from Abcam (red). COL was detected using a primary antibody for 
COL (RbpAb to collagen 1 ab34710). The secondary antibody used was Goat 
Anti-Rabbit IgG H&L (Alexa Fluor 555) (ab150078) from abcam (red). Cell 
nuclei were stained by DAPI (blue) for all samples, and actin was stained by 
phalloidin (green). The positive control was osteogenic media from Lonza 
((hMSC Osteogenic BulletKit). All other samples were grown in basal media 
(MSCGM BulletKit (PT-3238 & PT-4105) from Lonza. Peptides were displayed 
on M13 phages and developed into thin films for which the hMSCs were grown 
on for 26 days. This data shows that the phage films were able to upregulate 
the osteoblast marker protein, OPN. (e)  Fold change (2−∆∆𝐶𝑡) for osteopontin 
(OPN) expression of hMSCs after 26 days of culturing on phage films displaying 
the indicated peptide or controls. The sequence VHVPLHRGAVSA appears to 
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be the best with a fold change better than the Lonza osteogenic media. The 
sequence SGTQDSMVGWNK appears to be second best with a significant 
advantage over the wild type, but no difference from the Lonza osteogenic 
media. (f) Collagen (COL) type 1A fold change expression (a control that should 
be the same for all samples) of hMSCs after 26 days of culturing on phage films 
displaying the indicated peptide or controls. The gene expression was 
normalized to GAPDH (a reference gene). All fold changes are relative to a 
negative control (basal media with no peptides or phage) which represents the 
baseline at zero-fold change. All data are expressed as the mean + standard 
deviation (n=3, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). These data show that the 
aligned phage film structures (biophysical cue) could induce increased 
osteoblast gene expression as demonstrated by the upregulation of osteoblast 
genes in wild type films. Additionally, they show that the peptides 
VHVPLHRGAVSA and SGTQDSMGWNK further improved the differentiation of 
hMSCs into osteoblasts through a biochemical signaling route as they had a 
statistically significant advantage over wild type for OPN expression. 
3.3.4 Phage films support hMSC growth and proliferation 
 The phage films did support stem cell growth and proliferation. However, 
hMSCs not exposed to phages did grow at a statistically significant (P ≤ 0.05) 
faster rate within the first 47 and 71 hours. Slower cell proliferation on phage 
films is associated with osteoblast differentiation.8 Over longer periods of time, 
the hMSCs on the phage films did proliferate to densely cover the entire plate 
as can be seen in Figure. 14. Over time, the percent reduction of alamar blue 
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did increase for both the positive control and the phage films demonstrating that 
the cells could survive and proliferate on these phage films (Figure 15).  
 
Figure 15. hMSC cell proliferation on the phage films. Proliferation was 
measured as the percent reduction of alamar blue. The hMSCs were grown for 
47 h (a) or 71 h (b) before incubation with alamar blue and measurement of the 
absorbance at 570 nm and 600 nm. The percent reduction of alamar blue was 
then calculated (a higher percent reduction reflects more growth of the cells). 
The phage films did significantly lower cell proliferation, consistent with the 
earlier findings that a higher differentiation potential results in a lower 
proliferation potential of the stem cells. All data represent the mean + standard 
deviation of n=3 (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). The positive control is 
hMSCs grown in basal medium with no phages. 




3.3.5 Peptide-phage induced differentiation of hMSCs demonstrated by 
osteoblast marker proteins 
 The osteoblast marker protein osteopontin (OPN) was detected using 
immunofluorescence. Collagen type 1A (COL) was used as a control which 
shows the same level of expression (by eye) on each different peptide-bearing 
phage film. The results are shown in Figure 14. All peptides on phage films 
showed expression of osteopontin including the wild type phage film. This 
indicates that the highly ordered ridge groove structure of the phage films can 
induce osteoblast differentiation. Additionally, the peptide VHVPLHRGAVSA 
showed a qualitatively higher level of osteopontin protein expression than the 
other groups and a higher expression than the positive control (osteogenic 
media from Lonza). This data demonstrated that the phage films could induce 
osteogenesis, but it also showed a distinct advantage for the VHVPLHRGAVSA 
peptide sequence. The other sequences also showed differentiation but 
required more quantitative results rather than the qualitative 
immunofluorescence images which is later done using qPCR.  
3.3.6 Peptide-phage induced hMSC calcium deposits 
 Calcium nodule staining was done using Alizarin red at 14 and 26 days 
as shown in Figure 16 and Figure 17 respectively. At 14 days, hMSCs on the 
phage films and those cultured in osteogenic media showed an increase in 
calcium deposits at similar levels. In this test, it was not possible to establish a 
difference between osteoblast induction through the topography of the phage 
films vs from the peptides used on each phage film. However, it does show that 
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each phage film after 14 days is able to induce calcium deposits on the level of 
the positive control which is a leading product for osteogenesis. At 26 days, a 
major difference between the negative control, phage film samples, and the 
osteogenic media was observed. All phage film, although indistinguishable from 
each other by this method, performed substantially better than the negative or 
positive control. This indicates that the hMSCs are depositing a mineralized 
matrix which is indicative of osteoblast when cultured on phage films. 
Additionally, the phage films may be an alternative to using osteogenic media 




Figure 16. Calcium (red) nodule staining (14 days). Briefly, hMSCs were 
seeded onto either phage films having the indicated peptides or the indicated 
control groups. Calcium deposits were stained with Alizarin red after 14 days of 






Figure 17. Calcium (red) nodule staining (26 days). Briefly, hMSCs were 
seeded onto either phage films having the indicated peptides or the indicated 
control groups. Calcium deposits were stained with Alizarin red after 26 days of 
culturing hMSCs on phage films.  
3.3.7 Peptide-phage induced genetic upregulation of osteoblast marker 
genes 
 After the cells were cultured on the phage films in a basal media (non-
osteogenic media) for 14 or 26 days, the BMPR1A-binding peptide 
(VHVPLHRGAVSA) and BMPR1A/BMPR2 dual-binding peptide 
(SGTQDSMVGWNK) showed significantly higher capability in inducing the 
osteogenic differentiation than the BMPR2-binding peptide (RDYHPRDHTATW) 
and other peptides. This result is demonstrated by qPCR and 
immunofluorescence imaging of the osteogenic specific marker (osteopontin, 
OPN) at the gene and protein level, respectively (Figure 14d-e and Figure 18). 
More importantly, VHVPLHRGAVSA was the strongest inducer and even better 
than the commercial osteogenic differentiation inducing media after 26 days while 
SGTQDSMVGWNK did not show statistical difference in osteogenic 
differentiation induction in comparison to the commercial media after 26 days. 
For the 14-day time point group, the early differentiation capabilities of osteogenic 
media and VHVPLHRGAVSA were not statistically different, suggesting that the 
advantages of VHVPLHRGAVSA over osteogenic media only become apparent 
over a longer period of time. For the non-osteogenic marker (Type 1 Collagen, 
COL), all groups including all peptide groups and the no peptide group (wild type 
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phage) as well as the commercial osteogenic differentiation media showed no 
statistical differences after 26 days (Figure 14f). For the 14-day COL groups, 
TAKYLPMRPGPL showed less gene expression than RDYHPRDHTATW and 
SGTQDSMVGWNK while all other groups were not statistically different (Figure 
18b). All these data show that the BMPR1A-binding peptide (VHVPLHRGAVSA) 
and BMPR1A/BMPR2 dual-binding peptide (SGTQDSMVGWNK) are the best 
osteogenic peptides with the former even stronger than the commercial 
differentiation inducing media for longer time points. It should be noted that 
hMSCs were elongated on all phage films (Figure 14b), suggesting that the same 
topographical cue affected the cell morphology and differentiation similarly for all 
phage groups.  
 
Figure 18. Osteogenic differentiation of hMSCs on phage films after 14 days. 
(a)  Fold change (2−∆∆𝐶𝑡) for osteopontin (OPN) expression of hMSCs after 14 
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days of culturing on phage films displaying the indicated peptide or controls. 
The sequence VHVPLHRGAVSA appears to be the best with a fold change 
significantly better than the other peptides and no difference from the 
osteogenic media. (b) Collagen (COL) type 1A fold change expression of 
hMSCs after 14 days of culturing on phage films displaying the indicated 
peptide or controls. The peptides SGTQDSMVGWNK and RDYHPRDHTATW 
were upregulated relative to TAKYLPMRPGPL. All other conditions had no 
significant difference.  All Gene expressions were normalized to the reference 
gene, GAPDH. All fold changes are relative to a negative control (basal media 
with no peptides or phage) which represents the baseline at zero-fold change. 
All data represent the mean + standard deviation of n=3 (* P ≤ 0.05, ** P ≤ 0.01, 
*** P ≤ 0.001). This data shows that VHVPLHRGAVSA is as good as 
osteogenic media for upregulating the osteoblast marker, OPN at 14 days.  
3.4 Conclusion 
 The morphology of M13 phages was characterized by TEM and AFM. 
The M13 phages amplified were demonstrated to be filamentous in structure 
measuring ~1000 nm in length. The phages also demonstrated a self-assembly 
into highly ordered and aligned bundling structures brought about during a liquid 
crystalline phase transition. The natural ability of these phages to self-assemble 
into ordered structures was then used to develop a new, more reliable phage 
film generation strategy. This strategy produced highly organized phage films 
with an aligned ridge groove morphology. This morphology was shown to be a 
potent biophysical cue for osteoblast differentiation at a genetic level, protein 
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production level, and demonstrated large amounts of calcium deposition 
(greater than a leading company product). Novel possible osteogenesis 
inducing peptides discovered in Chapter 2 were then genetically displayed on 
the pVIII coat protein of M13 phages. When the peptide-bearing phage films 
were assembled, they allowed for a side-by-side comparison of the effects of 
each peptide on differentiation relative to the wild type phage control. The 
peptides, VHVPLHRGAVSA and SGTQDSMVGWNK demonstrated exceptional 
abilities to induce osteoblast differentiation as indicated by osteoblast marker 
proteins, marker genes, and calcium mineral deposits. In particular, the peptide 
VHVPLHRGAVSA displayed on a phage film demonstrated an ability to 
differentiate hMSCs better than a leading company product, osteogenic media 
from Lonza. This work demonstrated that these newly discovered peptides are 
in fact osteoblast differentiation inducing peptides. When these peptides are 
combined with the biophysical cue of a highly ordered phage film, they may be 








Chapter 4: Elucidating the signaling pathway mechanism of 
newly discovered osteogenic peptides 
4.1 Introduction: Bone regeneration signaling pathways 
Efficient bone regeneration involves a combination of factors such as 
biophysical and biochemical cues which act upon cellular signaling pathways. 
Deficiency in activating the correct signaling pathways can result in fracture 
non-unions during bone healing.360 Conversely, the combined utilization of 
multiple osteogenic differentiation inducers which target multiple osteogenic 
differentiation pathways often results in enhanced bone repair.360-362The 
peptide-bearing phages developed in Chapters 2 and 3 were expected to 
provide both a biophysical cue due to their assembled, ordered structures as 
well as a biochemical cue due to the peptide displayed. The expectation due to 
the process of discovering these peptides is that they will signal through the 
BMP signaling pathway. As a reminder that process was done by biopanning 
against the receptors of BMP. However, until now, this presumption had not 
been studied. Additionally, no study has determined the signaling pathways wild 
type phage film structures trigger for osteoblast differentiation. Other than the 
BMP signaling pathway, there are alternate pathways which can induce 
osteogenesis. Some of the more prominent pathways include the Wnt/β-
catenin, Notch, and Hedgehogs pathways.363Additionally, among all of these 
pathways, there are multiple routes which can be followed. For example, in the 
BMP pathway, signaling can proceed by either Smad depended (Smad 1/5/8) 
or independent processes (p38 MAPK). Several of the interactions among 
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these pathways are summarized in Figure 19. Though even more synergy 
among pathways exist than can be shown clearly in this figure, it should be 





Figure 19. Several prominent signaling pathways for osteogenesis are shown. 
Key signaling steps within these pathways which were studied are highlighted in 
green. These are known transcription factors. This figure does not show every 
possible differentiation pathway or the details of every pathway, but it does 
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identify key targets in each pathway that indicate the pathway is active. This 
figure was assembled from information originating from many publications.125, 
362, 364-375 
4.2 Materials and Experiments 
4.2.1 Materials 
Anti-beta Catenin antibody (ab32572 from Abcam), Anti-Gli1 antibody 
(ab151796 from Abcam), Anti-Hes1 antibody (ab71559 from Abcam), Anti-p38 
antibody (ab197348 from Abcam), Anti-RUNX2 antibody (ab23981 from 
Abcam), Anti-SMAD 1/5/8/9 antibody (ab13723 from Abcam), Bone 
morphogenic protein 2 (Prospec), Bovine serum albumin (Sigma Aldrich), 
Dexamethasone (Sigma Aldrich), Dorsomorphin (ab120843 from Abcam),Goat 
Anti-Rabbit IgG H&L (Alexa Fluor® 488 ab150077 from Abcam),Human Hes6 
protein (ab132389 from Abcam), Human mesenchymal stem cells (Lonza), L-
Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma 
Aldrich),Mesenchymal stem cell basal medium for adipose, umbilical and bone 
marrow-derived MSCs (ATCC® PCS-500-030™), Mesenchymal stem cell 
growth kit for bone marrow-derived MSCs (ATCC® PCS-500-041™), Triton X-
100 (Sigma Aldrich). 
4.2.2 Immunofluorescence of osteoblast signaling pathway marker 
proteins 
 Phage films (or no film for controls) for each peptide sequence were 
prepared in 96-well plates according to the previously described protocol. The 
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plates were subjected to 12 hours of UV radiation and soaked in cell media in a 
cell incubator overnight prior to cell seeding. Next, 300 µL of 3.6x104 hMSCs / 
mL were then seeded into each well for each condition tested (3 biological 
replicates were included for every condition). The cells were then grown for 14 
days in hMSC basal media (Lonza) with regular media changes (every 2 days). 
For the BMP condition, 400 ng/mL of BMP-2 was incorporated into the medium. 
For the DAG condition, 10 µM concentrations of dexamethasone and 0.05 mM 
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate were incorporated 
into the cell medium. For the DAG + BMP-2 condition, the components of the 
BMP and DAG conditions were combined. The cells were then fixed by 
incubating in 4% paraformaldehyde for 10 minutes. Following fixation, the cells 
were washed 5 times with PBS, permeabilized with 0.2% Triton X-100 (2 
minutes), blocked with 5% bovine serum albumin solution for 1 hour, and 
washed 5 more times with PBS. The cells were then incubated with one of the 
following primary antibodies (diluted in PBS) for 12 hours: Anti-SMAD 1/5/8/9 
antibody (ab13723) (10 µg / mL), Anti-p38 antibody (ab197348) (1:100 dilution), 
Anti-RUNX2 antibody (ab23981) (10 µg / mL), Anti-beta Catenin antibody 
[E247] (ab32572) (1:250 dilution), Anti-Hes1 antibody (ab71559) (1:200 
dilution), Anti-Gli1 antibody (ab151796) (1:50 dilution). The cells were then 
washed 5 times with PBS. Each condition was then incubated with the 
secondary antibody, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) 
(1:1000 dilution) for 2 hours. The cells were washed again 5 times with PBS. 
The cells were then stained by DAPI (Millipore Sigma) according to the 
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manufacturer’s protocol followed by a final 5 washes with PBS. The cells were 
then imaged on a Nikon Eclipse Ti fluorescent microscope using the ∞ Ph1 
lens. The following capture times were used for each condition: DAPI (4.4 
seconds), SMAD 1/5/8/9 (10 seconds), RUNX2 (10 seconds), Hes1 (20 
seconds), Gli1 (20 seconds), Beta-Catenin (6 seconds). 
4.2.3 Selective inhibition effects on peptide signaling pathways 
  
 Phage films (or no film for controls) for each peptide were prepared in 
96-well plates according to the previously described protocol. The plates were 
subjected to 12 hours of UV radiation and soaked in cell media in a cell 
incubator overnight prior to cell seeding. Next, 300 µL of 3.6x104 hMSCs / mL 
were then seeded into each well for each condition tested. The cells were then 
grown in basal media (Lonza) for 14 days with regular media changes (every 2 
days). For the BMP condition, 400 ng/mL of BMP was incorporated into the 
medium. For the DAG condition, 10 µM concentrations of dexamethasone and 
0.05 mM L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate were 
incorporated into the cell medium. For the DAG + BMP-2 condition, the 
components of the BMP and DAG conditions were combined. 
 For inhibiting the BMP pathway, 1200 nM dorsomorphin was 
incorporated into the cell medium and prepared freshly for each media change 
as it is otherwise unstable. The dorsomorphin required the preparation of a 
concentrated stock solution in which dorsomorphin was dissolved in ethanol 
followed by sonication at 55 ℃ until dissolved. The stock was aliquoted into 
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smaller amounts stored at -20 ℃ which could be diluted in cell medium to use 
fresh on each media change. Dorsomorphin acts to inhibit the phosphorylation 
of Smad 1/5/8 by the BMP receptor complex causing a drop in Smad 1/5/8 
mRNA and protein levels. For inhibiting the Notch pathway, Human Hes6 
protein (3.92 nM) was mixed into each media change (purchased from Abcam). 
Hes6 inhibits Hes1 function and may also decrease Hes1 mRNA and protein 
levels.376-377  
 After 14 days of growth, the cells were fixed by incubating in 4% 
paraformaldehyde for 10 minutes. Following fixation, the cells were washed 5 
times with PBS, permeabilized with 0.2% Triton X-100 (2 minutes), blocked with 
5% bovine serum albumin solution for 1 hour, and washed 5 more times with 
PBS. The cells were then incubated with one of the following primary antibodies 
depending on the pathway being studied for 12 hours: Anti-SMAD 1/5/8/9 
antibody (ab13723) (10 µg/mL), Anti-Hes1 antibody (ab71559) (1:200 dilution), 
Anti-Gli1 antibody (ab151796) (1:50 dilution). The cells were then washed 5 
times with PBS. Each condition was then incubated with the secondary 
antibody, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) (1:1000 
dilution) for 2 hours. The cells were washed again 5 times with PBS. The cells 
were then stained by DAPI (Millipore Sigma) according to the manufacturer’s 
protocol followed by a final 5 washes with PBS. The cells were then imaged on 
a Nikon Eclipse Ti fluorescent microscope using the ∞ Ph1 lens. The following 
capture times were used for each condition: DAPI (4.4 seconds), SMAD 1/5/8/9 
(10 seconds), Hes1 (20 seconds), Gli1 (20 seconds). 
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4.3 Results and Discussion 
4.3.1 Synergistic activations of osteoblast differentiation pathways by 
osteogenic peptide phage films.  
 The possible signaling pathways of the two strongest osteogenic 
inducing peptides, VHVPLHRGAVSA and SGTQDSMVGWNK, were further 
evaluated. To sort out the signaling, hMSCs were cultured on phage films 
bearing the peptides for 14 days and immunofluorescence imaging was done in 
parallel under exactly matching imaging conditions for markers of the 
osteogenic pathways including the Hedgehog (Gli 1 marker), Notch (Hes1 
marker), BMP (Smad 1/5/8 or p38 MAPK markers), and Wnt (-catenin marker) 
pathways as shown in Figure 20.125, 362, 364-375, 378-390  For the BMP pathway,  
which goes through either Smad 1/5/8 or p38 MAPK, Smad 1/5/8 was 
upregulated for each of the peptide conditions while p38 MAPK was not. This 
indicates that the Smad 1/5/8 route is activated either directly and/or synergy 
exists between the Smad 1/5/8-mediated BMP pathway and another pathway. 
For the hedgehog pathway, Gli 1 was upregulated for the peptides 
VHVPLHRGAVSA, SGTQDSMVGWNK, and a combination of these 2 peptides. 
Gli1 upregulation by a combination of the two peptides was slightly more than 
that by each peptide alone. This indicates that each peptide upregulates this 
pathway, and using two peptides together synergistically upregulates it further. 
For the Notch pathway, all peptides on the phage films were upregulated 
equally relative to the basal condition. This indicates that the phage film 
topography, which is the same for all phage films, is likely a potent activator of 
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the Notch pathway. The Wnt pathway appeared to be the same for all 
conditions (with or without peptides) and thus was likely unaffected by the 
peptides we discovered.  
 
Figure 20. Immunofluorescence showing signaling (green) among osteogenic 
pathways. The peptide-based phage films have an advantage in Hedgehog 
(Gli1 marker) and BMP (Smad 1/5/8 marker) signaling. The phage film 
topography appears to have an advantage in Notch (Hes1) signaling. 
4.3.2 Inhibition of differentiation pathways 
To further clarify the impact of the peptides, VHVPLHRGAVSA and 
SGTQDSMVGWNK, on the upregulation of the BMP, Hedgehog, and Notch 
pathways, specific inhibitors were used to selectively disrupt one of the 
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pathways followed by observation of the impact on the other pathways (Figure 
24, Figures 21-23). For all studies, hMSCs were seeded onto osteogenic-
peptide bearing phage films or control conditions followed by culturing for 14 
days.  All studies were done in parallel using the same stocks of cells, 
inhibitors, and imaging conditions for optimal side-by-side comparison.  
First, the Hedgehog pathway was examined while other pathways were 
inhibited (Figure 21). Dorsomorphin was used to inhibit the Smad 1/5/8 
phosphorylation to effectively suppress the BMP pathway.373 When the BMP 
pathway was inhibited, the Hedgehog pathway remained upregulated in all 
peptide conditions. Next, Hes6 was used to inhibit Hes1 function, and thus the 
Notch pathway was inhibited.376-377 Suppression of the Notch pathway failed to 
affect the Hedgehog pathway, either. Therefore, the increased signaling caused 
by the peptides VHVPLHRGAVSA and SGTQDSMVGWNK in the Hedgehog 
pathway were independent of BMP and Notch signaling. This shows that the 
Hedgehog pathway is a key pathway for differentiating the hMSCs into 
osteoblasts using the peptides VHVPLHRGAVSA and SGTQDSMVGWNK.  
It has already been shown in Figure 20 and Figure 23 that BMP signaling 
is upregulated by the peptides VHVPLHRGAVSA and SGTQDSMVGWNK. To 
further examine the signaling mechanism of this upregulation, the BMP pathway 
was examined while either the Notch or BMP pathways were inhibited. It should 
be noted that the BMP pathway under the inhibitor Numb of the Hedgehog 
pathway was not studied due to the significant cytotoxicity and apoptosis 
upregulation caused by the Numb inhibitor (also confirmed by us).391 First, the 
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Notch pathway was inhibited using Hes6. This resulted in a major drop to BMP 
signaling (via Smad 1/5/8) for the peptide SGTQDSMVGWNK. The other 
peptide, VHVPLHRGAVSA experienced only a minor drop in BMP signaling 
indicating less of a reliance on synergy with Notch signaling. The condition 
VHVPLHRGAVSA also maintained higher levels of BMP signaling than the 
control groups even when Notch signaling was disrupted. Additionally, when the 
BMP pathway was inhibited, the peptides still maintained an advantage in BMP 
signaling over the control conditions, indicating some degree of robustness for 
the peptides to upregulate BMP pathway. Therefore, the BMP pathway is an 
important synergystic acting pathway for the peptides, and the peptide 
VHVPLHRGAVSA has the greatest advantage in BMP signaling.  
Lastly, the Notch pathway was examined while the Notch or BMP 
pathways were inhibited. It has already been shown that without inhibitors, 
there is an equal upregulation of Notch signaling for all phage film conditions 
over other controls (Figure 20 and Figure 22). Hes6 is a notch pathway inhibitor 
that acts to inhibit Hes1.376-377 When the Notch pathway was inhibited using 
Hes6, the level of the Noth signaling marker (Hes1) was dramatically lowered 
for the no peptide group (wild type phage film) (Figure 22). The level of Hes1 
was also lowered for the peptide-displaying phage groups, but still obviously 
higher than that for the  no peptide and other control conditions (Figure 22). 
This indicates that peptide-enabled BMP and Hedgehog pathways have 
synergy with the Notch pathway for the peptide-displaying phage groups; when 
the Hes6 was intended to inhbit the Notch pathway, the synergy reduced the 
119 
 
level of such inhibition.  Hence, next, the Notch pathway was examined when 
the BMP pathway was inhibited with dorsomorphin. For the no peptide group 
(wild type phage), the Notch signaling by the phage substrates was reduced 
dramatically. The peptide groups also had decreased Notch signaling when the 
BMP pathway was inhibited. These results further indicate the synergy between 
the Notch signaling (via phage film topography) and BMP pathway (via 
peptides). Namely, inhibiting Notch signaling of the phage film topography 
became less favored for no peptide group (just wild type phages) than for 
peptide group (peptide-dispplaying phages) due to the synergy.  When the 
Notch signling was inhibited, the level of inhibition was higher for the peptide 
SGTQDSMVGWNK group than for another peptide VHVPLHRGAVSA. Both 
peptides still maintained higher Notch signaling than the controls or wild type 
condition, indicating less dependence on the other two signaling pathways than 
(wild type) phage topography mediated notch signaling. In summary, the Notch 
signaling upregulation under all phage film conditions is likely a result of 
biophysical cues from the topography of the phage film which is approximately 
equivalent for all phage film conditions. This further confirms that the two 






Figure 21. The effects of inhibiting Smad 1/5/8 (BMP pathway) and Hes1 
(Notch pathway) on Gli1 (Hedgehog pathway) protein levels. Dorsomorphin was 
used to inhibit the phosphorylation of Smad 1/5/8 by the BMP receptor complex 
at a concentration of 1200 nM, possibly causing a decrease in Smad 1/5/8 
mRNA and protein levels373. Hes6 was used to inhibit Hes1 function376 and 
possibly lower mRNA levels of Hes1377. Gli1 (Hedgehog pathway) levels are 
shown in green. Cell nuclei were stained using DAPI (blue). Without inhibitors, 
the peptides have a clear advantage in promoting Gli1 (Hedgehog pathway) 
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levels relative to wild type phage. Inhibiting the BMP and Notch pathways 
appeared to have little to no effect on the benefits of the peptides in the 
Hedgehog pathway as demonstrated through Gli1 protein levels. Therefore, the 
peptides have a considerably large effect on the Hedgehog signaling pathway 





Figure 22. The effects of inhibiting Smad 1/5/8 (BMP pathway) and Hes1 
(Notch pathway) on Hes1 (Notch pathway) protein levels. Dorsomorphin was 
used to inhibit the phosphorylation of Smad 1/5/8 by the BMP receptor complex 
at a concentration of 1200 nM, possibly causing a decrease in Smad 1/5/8 
mRNA and protein levels.373.Hes6 was used to inhibit Hes1 function376 and 
possibly lower mRNA levels of Hes1377. Hes1 (Notch signaling) is shown in 
green. Cell nuclei were stained using DAPI (blue). Without inhibitors, the 
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individual peptide-displaying phage films did not show an advantage over the 
wild type phage film, but all films showed an advantage over the control 
condition indicating that the Notch pathway may be an essential component of 
the ability of wild type phage films to differentiate hMSCs into osteoblasts. Wild 
type phage film Notch signaling was devastated by inhibition of either the BMP 
or Notch pathways as evidenced by a steep drop in Hes1 protein levels. This 
indicates that the natural ability of the topography of phage films to differentiate 
hMSCs into osteoblasts is likely dependent upon Notch signaling. However, the 
drop in wild type phage film Notch signaling upon preventing the 
phosphorylation of Smad 1/5/8 in the BMP pathway indicates some 
dependency of the Notch signaling on the BMP pathway being functional. It is 
likely from the data that wild type phage film upregulates the Notch pathway but 
still requires the BMP pathway to be functional for proper signaling to occur. 
Additionally, the peptide-displaying phage films showed a heavy drop in Notch 
signaling when either the Notch or BMP pathways were inhibited. However, 
they did not drop as far as the wild type phage film, indicating that the peptide-
displaying phage mediated Notch signaling is less dependent on the other two 
signaling pathways than the wild type phage mediated Notch signaling. 
Additionally, the drop in Hes1 (notch pathway) levels caused by inhibiting Smad 
1/5/8 (BMP pathway) indicates that the peptide-displaying phage films do 
benefit from BMP signaling. Taken with data from Figure 23 (the next figure), it 
is likely the additional boosts in peptide-based BMP signaling as well as 
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Hedgehog signaling are responsible for the increased levels of Notch signaling 
for peptides relative to wild type phage films under inhibiting conditions. 
 
 
Figure 23. The effects of inhibiting Smad 1/5/8 (BMP pathway) and Hes1 
(Notch pathway) on Smad 1/5/8 (BMP pathway) protein levels. Dorsomorphin 
was used to inhibit the phosphorylation of Smad 1/5/8 by the BMP receptor 
complex at a concentration of 1200 nM, possibly causing a decrease in Smad 
1/5/8 mRNA and protein levels373. Hes6 was used to inhibit Hes1 function376 
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and possibly lower mRNA levels of Hes1377. Smad 1/5/8 is shown in green. Cell 
nuclei were stained using DAPI (blue). With no inhibition, the peptides have a 
clear advantage in Smad 1/5/8 protein levels relative to wild type phages and 
controls. Inhibiting Hes1 (Notch pathway) caused a major drop in the peptide 
film BMP signaling for the peptide SGTQDSMVGWNK, but only a minor drop 
for the peptide VHVPLHRGAVSA. 
4.4 Conclusion 
Combining the results of the inhibition studies, the peptides 
VHVPLHRGAVSA and SGTQDSMVGWNK were demonstrated to signal 
through both the BMP and Hedgehod pathways. For the BMP pathway, we 
propose that the peptides bind to the BMPRs, which then initiate the 
phosphorylation of Smad 1/5/8 (Figure 24). Smad 1/5/8 is then complexed with 
Smad 4, which will lead to upregulated osteoblast differentiation genes. We also 
propose that the peptides upregulate the Hedgehog pathway by improving the 
production of the osteogenic transcription factor Gli1 independently of the BMP 
or Notch pathways. Lastly, we propose that the osteogenic capabilities of the 
phage film topography (i.e., not the peptides displayed on the film) can be 
attributed to increased Notch signaling but are not independent of BMP 
signaling synergy. Figure 24 gives an overview of the most important 
interactions discovered as described above. This figure was generated using 




The discovery of new osteogenic growth factor peptides serves as a 
proof of concept for our technique summarized in Figure 25. Phage display can 
identify a peptide binding to virtually any receptor for a given growth factor. By 
biopanning on the receptor targets of growth factors, we can produce a short 
peptide mimetic for those growth factors. Relative to recombinant proteins, 
these growth factor mimetic peptides are cheaper and less immunogenic. 
These short peptides can also be easily immobilized on substrates with greater 
control over their orientation, dispersal rate, and maintenance of functionality 
relative to recombinant protein growth factors.321-322 We believe that our 
technique can be applied to find new short peptide growth factors capable of 
mimicking full protein growth factors for any known target. Once a peptide 
mimicking a growth factor is discovered, it can be integrated onto the scaffolds 
or implants for tissue repair and regeneration. Hence, our strategy opens up a 
new avenue to the discovery of a short peptide that can perform the same 




Figure 24. The possible signaling pathway targets of the osteogenic peptides 
and phage films. The pathways have been greatly simplified to show the known 
points affected by the peptides or film topography. The peptides signal through 
the BMP pathway and upregulate Smad 1/5/8. The peptides also upregulate 
Gli1 in the Hedgehog pathway through a mechanism independent of the BMP 
or Notch pathways. The phage film topography causes an upregulation of Hes1 
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in the Notch pathway. The abbreviations are as follows: CSL (CBF1, 
Suppressor of Hairless, Lag-1), RAM (RBP-Jkappa-associated module 
domain), ANK (Ankyrin repeats), MAML-1 (Mastermind-like), Hes 
(hairyenhancer of split), Gli1 (glioma-associated oncogene 1), Smad (Small 
Mothers Against Decapentaplegic), BMPR1A (BMP receptor type 1A), BMPR2 
(BMP receptor type 2). Synergy exists between all pathways but is not shown. 
A great number of other factors exist within each pathway and are not shown 
for simplicity. Blue arrows indicate upregulation of an osteogenic pathway. Red 
arrows indicate inhibition targets for the studied points of each pathway. The 
structures of different proteins shown in this figure are obtained from the PDB 
according to their identities (Patched homolog 1: 6E1H; Gli1: 2GLI; 
Osteopontin: 3CXD; BMPR2: 3G2F; BMPR1A: 2K3G; Smad 1: 1KHU; Complex 
with Smad4: 5MEZ; Notch1: 4CUF, 5KZO, 3I08; Notch1 transcription complex: 







Figure 25. In vitro work summary of the use of phages displaying BMPR-binding 
peptides to induce the differentiation of hMSCs into osteoblast cells. (a) In vitro 
biopanning against BMPRs to screen BMPR-binding peptides out of a phage-
displayed random peptide library. Two types of BMPRs are used as biopanning 
targets, including BMPRI and BMPRII. (b) Assembly of M13 phage nanofibers 
displaying the BMPR-binding peptides into a film and culturing of MSCs on the 
resultant film to induce the osteogenic differentiation of MSCs. (c) Possible 
mechanism by which M13 phage nanofibers displaying the BMPR-binding 
peptides interact with the BMPR on the MSCs to trigger the osteogenic 
differentiation. The BMPR-binding peptides bind to BMP receptors and can 
upregulate osteoblast gene expression in addition to the unique topography of 











Chapter 5: Development of hybrid bone regenerative materials: 
A combination of 3D printing, phage display, and freeze 
casting 
5.1 Introduction 
5.1.1 Personalized 3D printed bone regenerative scaffolds 
There is a pressing need for bone regenerative procedures due to skeletal 
deformities, removal of bone tumors, non-unions (failure of healing broken bone), 
avascular necrosis, and osteoporotic fractures.393-399 Repairing large bone 
defects in load-bearing sites poses a major challenge as replacement implants 
need to have the appropriate mechanical strength and biocompatibility.262, 400-402 
3D printing is a versatile approach since implants can be customized to fit any 
patient-specific complex defect within its resolution capabilities (16 µm resolution 
is achievable).402-413 This is done by first using MicroCT to image a patient’s 
defect and generate a computer model. A 3D printer then generates a custom 
implant to fit the defect.414-415 For bone defects, titanium (Ti) and its alloys, the 
materials clinically used for bone implants due to their excellent mechanical 
properties,416 are a desirable choice for generating porous implants by 3D 
printing to overcome the weaker mechanical properties of materials such as 
ceramics and polymers. 3D printing with titanium alloys is currently being 
clinically investigated for use in cranial and jaw implants, but could be applied 
universally for all types of bone defects clinically.417 Compared to alternate 3D-
printed bone materials, titanium alloys have the major advantage of being 
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mechanically strong enough for load bearing sites.418 Titanium alloys are also 
inherently bioinert, making them an ideal implantable material.418 However, there 
are several major issues in the field of bone implants which can be improved 
upon.419 Specifically, the resultant implants still lack the capability of efficiently 
inducing bone formation to achieve excellent integration with the surrounding 
bone tissues.419  Therefore, improving regenerative capabilities of 3D printed 
titanium alloy implants is still a great challenge in repairing bone defects in load-
bearing sites. Bone implants need to closely mimic the native extracellular matrix 
(ECM) which can lead to improved cell adhesion, differentiation, proliferation, 
and tissue regeneration.419 These qualities are essential for the bone implant to 
be in harmony with the native environment, ensuring that the defect area can be 
replaced with functional, healthy tissue having little or no reparative scar 
formation.419 Additionally, microscale features that allow for cell penetration, 
nutrients diffusion, vascularization, cellular differentiation, and spatial 
organization of cellular growth are essential.419 Here, we propose fine tuning the 
microscale features of implantable 3D printed titanium by coating it in a precisely 
aligned bone-mimetic structure made up of M13 phages. M13 phages are a 
human-safe filamentous virus measuring roughly 1000 nm in length. To align 
these phages into a bone-mimetic lamellar structure, a process called freeze 
casting can be used. This process uses the directional growth of ice crystals to 
push solid materials (phages in this case) into lamellar structures. When this 
process is utilized on phages, the resulting filamentous lamellar structures 
resemble that of collagen matrices in natural bone.420-423 This allows for precise 
133 
 
control over mimicking the natural environment of bone-regenerative osteoblast 
cells. Additionally, phages have the benefit of being able to display short growth 
factor mimetic peptides. We have recently discovered the peptides 
VHVPLHRGAVSA and SGTQDSMVGWNK which have been demonstrated to 
induce human mesenchymal stem cells (hMSCs) to differentiate into osteoblasts. 
By combining personalized 3D printing, precise microenvironment structural 
control, and growth factor mimetic peptides, we have developed a new technique 
to improve bone regeneration. This technique could potentially be extended to 
coat any material with phages bearing growth factor mimetic peptides specific to 
the desired tissue type.  
5.1.2 Freeze casting organized bone-mimetic lamellar structures 
 Freeze casting is a process in which the directional growth of ice crystals 
can push solid materials dissolved in an aqueous solution into an organized 
pattern. Upon being completely frozen, the ice can be removed through 
sublimation during which the sample is put under vacuum. When the 
directionality of the ice crystal growth is controlled by precise manipulations of 
the temperatures on all sides of the liquid suspension, complex, ordered 
structures can be formed.424-425When ice crystals are either grown directionally 
from the bottom up, top down, or a combination of these two, a lamellar structure 
can be obtained. A lamellar structure closely mimics the natural structure of 
bone.426 Thus, lamellar structures are preferred to help provide a biophysical 
environmental cue for bone regeneration. 
 




Calcium nitrate tetrahydrate, carbon dioxide gas, ethanol, 1-ethyl-3-(3 
dimethylaminopropyl) carbodiimide hydrochloride, isoflurane, Lidocaine, linoleic 
acid, octadecylamine, oxygen gas, paraformaldehyde, polyethylene glycol–
8000, sodium hydroxide, sodium phosphate. 
5.2.2 3D printing titanium alloy 
3D printed titanium implants were created using a biocompatible metal 
alloy consisting of titanium, aluminum, and vanadium (Ti-6Al-4V, 6:4:90, Al: V: 
Ti, wt%) which is among the most commonly used titanium alloys for 
biomedical implants.427-428 Specifically, a design of the desired porous scaffold 
was created in the digital format known as an STL (Stereo Lithography) file 
using a computer-aided design (CAD) software. Then commercial Ti-6Al-4V 
alloy powder (Sandvik, Sweden) was printed into an implant in pure Ar gas 
according to the STL file, by means of selective laser melting (SLM) through a 
commercial laser-based 3D printer (Concept LASER M2) specialized for 
printing metallic powder. The 3D printer was equipped with a Yb-FaserLaser 
with a focus beam diameter of 50 µm. The SLM parameters during 3D printing 
included a laser power of 100 W, a scan speed of 650 mm/s, a scan spacing of 
70 µm, and a layer thickness of 30 µm. The scaffolds were cylindrical in shape 
with a height of 8 mm and a diameter of 5 mm. The pores within the scaffold 
measured ~200 µm in diameter. 
5.2.3 Creating a double-sided freeze casting machine 
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 A double-sided freeze casting machine was built loosely based on a 
published design.429A double sided freeze casting system allows for greater 
control over generating constant solidification velocities and can produce nearly 
constant lamellae spacing over a longer sample height relative to a one-sided 
freeze casting system.429Two Omega temperature controllers were integrated 
into the double sided freeze casting system to allow for a temperature control 
system. The controllers were programmed to either be able to allow for drops of 
3 ºC / minute for both the top and bottom copper rods or for a drop of 3 ºC / 
minute for just the bottom rod while maintaining the top rod at 0 ºC (typically 
done unless otherwise stated). The final temperature was -135ºC. Reservoirs of 
liquid nitrogen were held in contact with the top and bottom copper rods to 
provide a cold source.  Any liquid suspension to be freeze casted could fit in 
various sizes of containers which all fit in between the two copper rods. The 
containers consisted of top and bottom copper pieces which perfectly fit against 
the copper rods and a plastic cylindrical container that goes between them. The 
cylindrical container is open on both ends.  
5.2.4 HAP nanorod synthesis, TEM imaging of HAP, and powder X-Ray 
diffraction of HAP 
 Hydrophobic hydroxyapatite (HAP) nanorods were synthesized 
according to a published protocol.430 After synthesizing, the HAP nanorods 
were pelleted by centrifugation and washed with ethanol, pelleted in a 
centrifuge again, resuspended in water, frozen at -80 ºC, and freeze dried 
overnight. The nanorods were then ball milled overnight to obtain a fine HAP 
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powder. For TEM imaging, 10 µL HAP nanorods suspended in water were 
pipetted onto a formvar-coated TEM grid. After 3 minutes, any extra liquid was 
wicked away using a filter paper and the grid was dried using a hair dryer. The 
HAP nanorods were then imaged on a Jeol 2000 TEM at 200KV and 100K 
Magnification. Additionally, X-Ray diffraction was done on the ball-milled HAP 
powder.  
5.2.5 Generating bone mimetic lamellar structures of combination of 
phage, hydroxyapatite, and collagen through freeze casting, cross 
linking, and sintering processes 
 Various solutions for freeze casting were optimized and their 
components are listed in the table below. Each solution was freeze casted 
using the constructed double-sided freeze casting machine with a temperature 
drop of 3 ºC/minute and a final temperature of -135 ºC. The frozen solutions 
were then freeze dried overnight. Images of the unprocessed scaffolds were 
taken by SEM after sputter coating with gold/ palladium. Additional processes 
were also done to strengthen composite scaffolds. 
For the phage + collagen + HAP scaffold, crosslinking with 1-ethyl-3-(3 
dimethylaminopropyl) carbodiimide hydrochloride (EDC) was done. Briefly, the 
scaffold was dropped into a solution of 200 mM EDC in ethanol. After 
incubating for 12 hours, the scaffold was placed in 0.1 M sodium phosphate for 
2 hours to hydrolyze any unreacted o-isoacylurea intermediate. The scaffold 
was then soaked in PBS (pH 7.4) for 2 hours. To image this scaffold, the 
scaffold was dehydrated in a series of ethanol solutions (20%, 50%, 70%, 80%, 
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90%, 95%, 100%) incubating at each step for 20 minutes followed by critical 
point drying. The scaffold was then sputter coated with gold/palladium before 
SEM imaging. 
For the pure HAP scaffolds, sintering was done after the freeze-drying 
process. For the first phase of sintering, the temperature was raised from 25 ºC 
to 550 ºC linearly over a time span of 2 hours and 55 minutes. The temperature 
was then held at 550 ºC for 2 hours. The temperature was then raised to 950 
ºC linearly over 2 hours and 13 minutes. The temperature was held at 950 ºC 
for 5 minutes followed by linear cooling to 25 ºC over 5 hours and 8 minutes. 
For imaging, the scaffold was then gold/palladium sputter coated and imaged 
by SEM.  













Pure Phage 1 mL of 
9x1013 
phages/mL 




1 mL of 
9x1013 
phages/mL 
100 µL of 
9.87 mg/mL 
25 mg None 
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5.2.6 Freeze casting M13 phages onto 3D printed titanium 
 The titanium alloy scaffolds (cylindrical measuring 8 mm in height and 5 
mm in diameter) were rinsed 3 times in distilled water followed by autoclaving. 
The scaffolds were then coated in poly-L-lysine by soaking in 2.5 mL of poly-L-
lysine per 5 scaffolds in a 24-well cell culture plate for 30 minutes. The poly-L-
lysine was then discarded, and the scaffolds were allowed to dry in a sterile 
hood overnight. In a sterile biological safety cabinet, 2 scaffolds were loaded 
into the sterile freeze casting holder (sterilized by autoclaving). 2 mL of sterile, 
filtered phage solution (3.0x1013 phages/mL) was pipetted into the casting 
holder and directly into the pores of the titanium scaffolds. The solution was 
allowed to incubate at room temperature for 30 minutes so that phages could 
stick better to the scaffold. The scaffolds and phage solution were then freeze 
casted in the double-sided freeze casting machine with a temperature drop of 3 
ºC/minute on the lower contact point and a constant 0 ºC on the upper contact 
point. The final temperature for the lower contact point was -135 ºC. The frozen 
scaffold and solution was then freeze dried overnight. For cell seeding, the 
scaffold was then soaked overnight in cell medium followed by seeding 3.6x104 
hMSCs onto the scaffold the next day in new medium. After 1 day of culturing, 
the scaffolds were implanted into the rat radial bone defect model. 
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5.2.7 Scanning electron microscopy, EDS, and cell attachment to 
scaffolds 
After the freeze casting or cell seeding protocols for the titanium 
scaffolds, the scaffolds were fixed in 4% paraformaldehyde solution for 10 
minutes. The scaffolds were then washed 5 times in PBS (pH 7.4). The 
scaffolds were then dehydrated in a series of ethanol dilutions (20%, 50%, 
70%, 80%, 90%, 95%, 100%) incubating at each step for 20 minutes followed 
by critical point drying. The scaffold was then sputter coated with gold/ 
palladium before SEM or energy-dispersive X-ray spectroscopy (EDS) imaging. 
5.2.8 Mechanical strength testing 
 Compression tests were done to determine the mechanical properties of 
the titanium scaffolds. The tests were performed using a Test Resources 
mechanical tester (800LE4AT30). The load cell value was 12.5 kN at room 
temperature. The cross-head speed was set to 0.008 mm/min. The elastic 










F = Force (N) 
R= radius of cylindrical sample 
H = height of sample (mm) 





modulus was calculated from the linear region of the stress-strain curve using 
the 0.2% offset method. For the compression tests, the following equations 
were used to generate the stress strain curve. 
For the healthy bone samples, a three-point bending test was done. The 
tests were also carried out using a Test Resources mechanical tester 
(800LE4AT30). The load cell value was 12.5 kN and the cross-head speed was 
set to 0.005 mm/min. The cross-head speed was set to 0.008 mm/min. The 
elastic modulus was calculated from the linear region of the stress-strain curve 
using the 0.2% offset method. For three-point bending, the following equations 
were used to generate the stress strain curve. 
 
















I = 𝑚𝑜𝑚𝑒𝑛𝑡 𝑜𝑓 𝑖𝑛𝑒𝑟𝑡𝑖𝑎 𝑎𝑏𝑜𝑢𝑡 𝑎 𝑏𝑒𝑛𝑑𝑖𝑛𝑔 𝑎𝑥𝑖𝑠 𝑜𝑓 
𝑎 ℎ𝑜𝑙𝑙𝑜𝑤 𝑐𝑦𝑙𝑖𝑛𝑑𝑒𝑟 
F = Force (N) 
c = outside radius of bone (mm) 
L = length of beam (mm) 





5.2.9 Generating a rat radial bone defect model 
A rat radial bone defect model (removal of an 8 mm section of the radius 
bone) was generated for evaluating the bone regeneration potentials of these 
3D printed titanium scaffolds. The animals were anesthetized by inhalation of 
4% isoflurane/oxygen (v/v) mixture using an anesthesia machine (VT-110 small 
animal anesthesia machine) and then with 2% isoflurane (v/v) during the 
surgical operation with a non-rebreathing system. A radial defect of 8 mm was 
created using a rongeur unit (bone cutter). The defect was thoroughly rinsed 
with isotonic saline and any bone fragments were removed. After implanting the 
scaffold, the incision was closed with 5-0 sized silk sutures. A subcutaneous 
injection of 2% Lidocaine (w/v) was administered immediately directly into the 
surgical area under the skin after closure of the incision to relieve pain. At the 
end of the surgery, the animal was administered a subcutaneous injection of 
sterile saline at a dose of 10 mL/kg per surgery hour and provided pure oxygen 
by a non-rebreathing system until it awakened from the isoflurane anesthesia. 
A dose of carprofen (anti-inflammatory drug) solution was subcutaneously 
given (4 mg/kg) every 12 hours for 7 days.  
5.2.10 Preparation and fixation of harvested bone defect tissues 
 After 4 weeks and 12 weeks, Animals (N=5) were euthanized by CO2 
asphyxiation. The sections of the arms containing the implant (at the radius 
bone) were then cut way from the rest of the animal using bone cutters. The 4-
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week implant samples were fixed in 10% (w/v) neutral formalin solution for 4 
days. The 12-week samples were fixed in 4% paraformaldehyde for 4 days. 
Paraformaldehyde was used as it can produce better CD31 vascularization 
stains relative to fixing with formalin. The samples were then placed in a 
solution of 70% ethanol to 30% water (v/v).   
5.2.11 Hematoxylin and Eosin Tissue Staining 
 The equipment necessary for sectioning titanium is very rare and 
expensive. I would like to thank Dr. Khandaker (University of Central 
Oklahoma) and his student, Sadegh (Univeristy of Central Oklahoma) for their 
help during the sectioning process.  
The tissue sections were deparaffinized and hydrated with distilled 
water. Hematoxylin was applied to the sample with enough volume to cover the 
tissue section followed by incubation for 5 minutes. The mounted tissue slide 
was then rinsed in 2 changes of distilled water (sections were allowed to soak 
for 15 seconds on each exchange of water). Enough Bluing Reagent was then 
added to the tissue section to completely cover it followed by incubation for 10-
15 seconds. The slides were then rinsed again in 2 changes of distilled water 
allowing 15 seconds of contact with the water each time. The slides were then 
dipped in 100% ethanol for 10 seconds. The excess ethanol was blotted off. 
Enough Eosin Y Solution was then added to completely cover the tissue 
section followed by incubation for 2-3 minutes. The slides were then rinsed in 
100% ethanol for 10 seconds. Next, the slides were dehydrated in 3 changes of 
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100% ethanol allowing 1-2 minute incubation times at each exchange of 
ethanol. The sections were then cleared and cover slipped.  
5.2.12 Von Kossa tissue Staining 
 The sections were deparaffinized and hydrated in distilled water. The 
slides were then incubated in Silver Nitrate Solution (5%) for 30-60 minutes 
while exposed to an ultraviolet light. The slides were then rinsed in 3 changes 
of distilled water. The slides were then incubated in Sodium Thiosulfate 
Solution (5%) for 2-3 minutes. The slides were then rinsed for 2 minutes in 
running tap water followed by two changes of distilled water. The slides were 
then incubated in Nuclear Fast Red Solution for a duration of 5 minutes. Next, 
the slides were rinsed for 2 minutes in running tap water followed by 2 changes 
of distilled water. The samples were then dehydrated rapidly in 3 changes of 
fresh 100 proof ethanol. The slides were then cleared and mounted in synthetic 
resin.  
5.3 Results and Discussion 
5.3.1 Freeze casting machine performance 
 The double-sided freeze casting machine allowed for greater control 
over the linearity of the cooling rate of samples as shown in the figures below. 
Additionally, the top cold finger allows for control over the heat flux of the top of 
the sample. Another side benefit is that the sample can be completely sealed in 
a sterile container during the freeze casting when both a top and cold finger are 
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Figure 26. Double Sided Freeze Casting rates for the top cold finger (top) and 
bottom cold finger (bottom). The double-sided freeze casting system cooled at 
a very steady rate of 3 degrees Celsius per minute.  
 
Figure 27. An overlay of the top and bottom cold fingers freeze casting rates. 


































Figure 28. Temperature rates of the top (blue) and bottom (red) cold fingers in 
the double-sided freeze casting setup. In this run, the top cold finger was held 
at 0 ℃ while the bottom cold finger dropped at 3 ℃ / minute. The green shows 
the period of time where the cold fingers were adjusted and synchronized 
before reaching 0℃. 
 



































Figure 29. The temperature drop rate of a single-sided freeze casting system is 
shown. The system does not cool as linearly as the double-sided system and 
lacks a top cold finger to control the heat flux over the sample’s top surface.  
5.3.2 Hydroxyapatite powder X-Ray diffraction and TEM confirms 
synthesis of HAP nanorods 
 Hydroxyapatite nanorods were synthesized to be later used in freeze 
casting applications for bone regenerative scaffolds. Figure 30 shows the 
synthesized nanorods’ morphology. X-ray diffraction was also done on the 
nanorods which confirmed that the nanorods were composed of hydroxyapatite 
according to the (hkl) values shown in Figure 30.  






























Figure 30. Hydroxyapatite Ca5(PO4)3(OH) nanorods. The nanorods were 
synthesized, imaged by TEM (A), and characterized by powder x-ray diffraction 
(B). 
5.3.3 Just Phage and phage + hydroxyapatite characterization after freeze 
casting 
 Using the double-sided freeze casting machine built, several different 
lamellar scaffold structures could be created for their intended use in bone 
regeneration. Figure 31 shows the resulting lamellar structures. A close up of 
the scaffold containing just phage shows the fiber-like structure of M13 phages 
which form bundles within the scaffold. The pure phage scaffold was highly 
organized into a lamellar structure. However, pure phage scaffolds are rather 
weak to handle and will fall apart if not moved very carefully. They are not ideal 
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for load-bearing site bone regeneration. Additionally, the pure phage scaffolds 
will dissolve in water within minutes making them unsuitable for cell culture or 
cross-linking through EDC. When pure phage scaffolds are combined with HAP 
nanorods, the structure collapses and the scaffolds are too weak to visualize. 
Therefore, an additional component, rat tail collagen type 1 was added in parts 
C-F of Figure 32. Upon the addition of collagen, the scaffolds were stronger 
and could handle being combined with HAP as shown in C and D of Figure 31. 
However, these scaffolds were still easily degraded if not handled carefully and 
their durability in water was ~2 days. Therefore, additional strengthening was 
necessary which was provided by crosslinking in EDC. The cross-linked 
samples are shown in parts E and F of Figure 31. After crosslinking, the 
samples were stable in water or cell culture medium for greater than 2 weeks. 
However, their ability to regenerate bone in a load-bearing site was not possible 
as they had the consistency of a marshmallow. Due to the poor mechanical 
strength of this method, more mechanically strong methods were later pursued. 
However, this data does show that phages can be organized into a lamellar 
bone-like 3D structure using double-sided freeze casting. Additionally, upon 
strengthening the phages were semi-stable in water indicating some potential in 
vitro for 3D cell culture applications. These results were later used to develop a 




Figure 31. M13 phage scaffolds arranged through freeze casting and imaged 
by SEM. Pure M13 phage scaffolds at different magnifications (A and B). M13 
phages combined with collagen and hydroxyapatite nanorods at different 
magnifications (C and D). M13 phages mixed with collagen and hydroxyapatite 
which were cross-linked using EDC.  
 The double-sided freeze casting system was also used to generate 
hydroxyapatite scaffolds held together with an organic binder, PEG-8000. 
These scaffolds showed excellent lamellar structures as shown in Figure 32. 
However, these scaffolds easily dissolved in water and had a stiffness 
comparable to a marshmallow which is not close to ideal for load bearing 
applications. Therefore, the scaffolds were sintered. This process also served 
to burn off the PEG-8000 leaving only pure HAP left in the scaffolds. The 
resulting structures are shown in Figure 33. While the sintered HAP scaffold 
appears to be a bit shriveled relative to the un-sintered scaffold, the highly 
organized lamellar structure was maintained. Additionally, the scaffolds were 
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now more durable and hard in nature. However, the scaffolds were still not 
considered strong enough for load-bearing sites as they could be broken with a 
very modest amount of pressure. Therefore, this route is not recommended. 
However, these data do demonstrate the power of the double-sided freeze 
casting system for organizing bone regenerative materials into a lamellar 
structure which could have potential in vitro for 3D cell culturing. 
 
Figure 32. Freeze-casted HAP. (A) Center top view of scaffold; (B) Edge top 
view of scaffold; (C) zoomed in view of lamellar structure; (D) high 





Figure 33. Freeze casted HAP which has been sintered. (A) Center top view; 
(B-D) top view at increasing magnification. The lamellar structure can be seen. 
5.3.4 A combination of 3D printing, freeze casting, and growth factor 
mimetics to tune the microenvironment of implants 
 3D printed titanium implants were created using a biocompatible 
metal alloy consisting of titanium, aluminum, and vanadium (Ti-6Al-4V, 6:4:90, 
Al: V: Ti, wt%) which is among the most commonly used titanium alloys for 
biomedical implants.427-428 Specifically, a design of the desired porous scaffold 
was created in the digital format known as an STL (Stereo Lithography) file 
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using a computer-aided design (CAD) software. Then commercial Ti-6Al-4V 
alloy powder was printed into an implant in pure Ar gas according to the STL 
file, by means of selective laser melting (SLM) through a commercial laser-
based 3D printer (Concept LASER M2) specialized for printing metallic powder. 
The 3D printer was equipped with a Yb-FaserLaser with a focus beam diameter 
of 50 µm. The SLM parameters during 3D printing included a laser power of 
100 W, a scan speed of 650 mm/s, a scan spacing of 70 µm, and a layer 
thickness of 30 µm. The scaffolds were cylindrical in shape with a height of 8 
mm and a diameter of 5 mm (Figure 34). The pores within the scaffold 
measured ~200 µm in diameter which is important for cell penetration and the 
diffusion of nutrients throughout the scaffold (Fig. 2). When human 
mesenchymal stem cells (hMSCs) were cultured on these scaffolds they spread 
to cover both the top (Fig. 2Ac) and sides (Fig. 2Ad) of the scaffolds. Using 
EDS, the carbon contained in the cells could be visualized to show the 
locations of the cells (Fig 2Ac-d).  
To control the microenvironment on the scaffolds, M13 phage structures 
were assembled using freeze casting to generate similar lamellar structures to 
collagen in natural bone (cite) (Fig. 2Ba-b). This process was done by 
directionally freezing water from the bottom of the scaffold to the top at a 
cooling rate of 3 ℃ /min while maintaining a constant temperature of 0 ℃ on the 
top (Fig 1?). As the ice crystals form, they push the M13 phages into the 
lamellar spaces in between the ice. When the ice is removed through 
sublimation under a vacuum, highly lamellar fibrous phage structures are 
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leftover (Fig. 2Ba-b). The direction of the freezing controls the direction of the 
lamellar structures, and therefore the sides of the scaffolds are where the 
lamellar structures occur (Fig. 2Ba-b). After coating with phages, the scaffolds 
were seeded with hMSCs which can be seen from the top view (Fig. 2Bc) and 
side view (Fig. 2Bd). The cell structures can be clearly seen from the top view, 
(Fig. 2Bc) and the carbon in them creates a contrast against the titanium 
background. The amount of phages deposited are heavier on the sides of the 
scaffold (Fig. 2Ba-b and d) due to the freeze casting process. The cells can still 
be seen on the side view of the phage coated scaffolds (Fig. 2Bd), but both 
phages and cells have carbon and are thus both colored green by EDS. An 
additional control mechanism over the microenvironment of the cells was the 
introduction of the growth factor mimetic peptides VHVPLHRGAVSA and 
SGTQDSMVGWNK. These peptides were displayed on the major coat protein 
of the filamentous M13 phages allowing for optimal surface area exposure. The 
display of these peptides on the phages does not alter the lamellar structures 
created through freeze casting. By combining the precise structural control 
mechanisms of 3D printing and freeze casting with the power of phages 
bearing growth factor mimetic peptides, we have created a new method for 









Figure 35. 3D printed titanium scaffold coating results. Green represents 
carbon imaged by energy-dispersive x-ray spectroscopy (EDS). (A) The 
scaffolds without phages are shown (a and b). The scaffolds without phages 
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were seeded with cells which can be seen from the top view (c) and side view 
(d). (B) The scaffolds were coated by freeze casting with phages (a and b) 
creating an aligned lamellar pattern. The phage-coated scaffolds were then 
seeded with cells which can be seen from the top view (c) and side view (d) of 
the scaffolds. This data shows that the phage coating procedure can create 
lamellar bone-mimetic structures that support cell growth. The carbon in both 
cells and phages (green) clearly shows a contrast between the titanium and 
biological material. 
5.3.5 Mechanical strength properties of titanium-phage hybrid scaffolds 
show ideal bone-like properties in vivo 
 The mechanical properties of natural bone can have major effects 
on the health of the bone.431 Therefore, our 3D printed scaffolds were designed 
to mimic the properties of natural bone. To evaluate these mechanical 
properties, stress strain curves for 3D printed scaffolds and healthy bone 
samples were created. The average Young's modulus for titanium scaffolds 
before implantation into rats was 3.7917 ± 1.1284 𝐺𝑃𝑎. The average Young's 
modulus for titanium scaffolds implanted for 4 weeks was 3.8436 ±
0.7260 𝐺𝑃𝑎. The Young’s moduli of the titanium scaffolds before and after 
implantation were not statistically different indicating no degradation of the 
titanium. The average Young's modulus for healthy bone (4-week-old SD rats) 
was 10.1099 ± 5.1366 𝐺𝑃𝑎. No statistical difference was found between the 
Young's modulus for the titanium scaffolds and healthy bone. This data shows 
that the Young’s moduli of the titanium scaffolds and healthy bone are 
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comparable. The average maximum stresses before failure of the titanium 
scaffolds before implantation, implanted 4 weeks, and healthy bone (4 week old 
SD rats) were 305.9027 ± 14.2514 𝐺𝑃𝑎, 278.1823 ± 20.9649 𝐺𝑃𝑎, and 
229.1154 ± 79.8224 𝐺𝑃𝑎 respectively. There was no statistical difference 
between the maximum stress before failure for any of the conditions. This data 
demonstrates that the titanium alloy scaffolds are mechanically very similar to 
healthy bone.  
 
 
Figure 36. The mechanical properties of implanted scaffolds. (a-c) Replicate 
(n=3) stress strain curves for titanium scaffolds before implantation (a), for 
titanium scaffolds implanted 4 weeks (b), and for healthy bone after 4 weeks 
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(c). The young’s moduli for each sample were not significantly different (d). The 
maximum stress was also not significantly different (e). This data indicates that 
the titanium scaffolds do not degrade over time and are highly similar to natural 
healthy bone in terms of mechanical properties. All data represent the mean + 
standard deviation with n=3 repeats.  
5.3.6 Histological staining shows tissue and calcium deposits in scaffolds 
The 3D printed titanium scaffolds under each condition were harvested 
after 4 weeks of implantation in rats. The implants were fixed in 10% (w/v) 
neutral formalin solution followed by dehydration in a graded series of ethanol. 
The scaffolds were then embedded in a technovit resin followed by sectioning. 
H&E staining as well as Von Kossa staining were done from sections 
originating near the middle of the scaffolds. From the H&E staining, cells were 
able to penetrate deeply into the sample. The peptide conditions 
VHVPLHRGAVSA, SGTQDSMVGWNK, and the combination of these two 
peptides appeared to enhance the amount of tissue formation (Fig. 4). A Von 
Kossa stain indirectly stains for calcium by reacting silver ions with 
phosphates.432 This turns areas of intense calcium deposition black and lighter 
areas gray. The Von Kossa staining reveals that bone formation around some 
of the conditions as well as calcium deposition did occur (Fig. 5). In particular, 
the peptides VHVPLHRGAVSA, SGTQDSMVGWNK, and the combination of 
these two peptides demonstrated greater bone regeneration than the control 
groups. This demonstrates that our technique for coating scaffolds with growth 





Figure 37. Top down view of a section of each cylindrical-shaped implant 
condition stained with H&E after being implanted 4 weeks. The section was 
taken from the middle of the scaffold. The dark black grids are the titanium and 
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the cells can be seen in purple/pink. The scaffolds supported the penetration 
and growth of cells even to the deepest regions of the scaffolds. The peptide-
bearing phage samples VHVPLHRGAVSA, SGTQDSMVGWNK, and the 
combination of these two peptides appear to have more tissue growth within 




Figure 38. Von Kossa stains of 4-week implants in rat radial defect bone 
models viewed from the top down of the cylindrical scaffolds. The section was 
taken from the middle of the scaffold. The dark black grids are titanium. Other 
black areas are heavy calcium deposits. Gray areas indicate lighter calcium 
deposits. The lightly colored pink/purple are cells. The peptides 
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VHVPLHRGAVSA, SGTQDSMVGWNK, and the combination of these peptides 
appear to have more calcium deposition within and around the scaffolds.  
5.4 Conclusion 
 Phage-based scaffolds were created with lamellar structures resembling 
natural bone. However, the biodegradable phage scaffolds created from pure 
phage, phage and collagen, or additions of hydroxyapatite with phage were not 
suitable for load bearing site bone tissue repair due to poor mechanical 
strength. The strategy was adapted to coat 3D printed titanium implants with 
mechanical strengths much closer to that of natural bone. Each phage coating 
was genetically engineered to have osteogenic peptides displayed. The phage 
coatings were aligned in lamellar structures through freeze casting onto the 
titanium. In a rat radial bone defect model, bone regeneration was discovered 
in the areas surrounding the implant. Cell penetration deep into the implants 
was observed through H&E staining. New calcium deposits were found within 
and around the scaffolds resembling natural bone via a Von Kossa stain. While 
this study was limited to a radial defect model, the process is relevant to 
coating any material. This work may become very useful for coating dental 
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Supplementary Table 11. ANOVA statistical significance report corresponding 
to the ELISA data in Figure 10 (n=4 for all samples). The calculations were 
done using Prism software.  
1 way ANOVA for BMPR1A
Number of families 1
Number of comparisons per family 21
Alpha 0.05
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary
VHVPLHRGAVSA vs. SGTQDSMVGWNK 0.02425 -0.1237 to 0.1722 No ns
VHVPLHRGAVSA vs. Wild Type 0.3808 0.2328 to 0.5287 Yes ****
VHVPLHRGAVSA vs. TAKYLPMRPGPL 0.1243 -0.02371 to 0.2722 No ns
VHVPLHRGAVSA vs. DYHDPSLPTLRK 0.287 0.1390 to 0.4350 Yes ****
VHVPLHRGAVSA vs. GNNPLHVHHDKR 0.3803 0.2323 to 0.5282 Yes ****
VHVPLHRGAVSA vs. NAKYPTMRPGPL 0.3 0.1520 to 0.4480 Yes ****
SGTQDSMVGWNK  vs. Wild Type 0.3565 0.2085 to 0.5045 Yes ****
SGTQDSMVGWNK  vs. TAKYLPMRPGPL 0.1 -0.04796 to 0.2480 No ns
SGTQDSMVGWNK  vs. DYHDPSLPTLRK 0.2628 0.1148 to 0.4107 Yes ***
SGTQDSMVGWNK  vs. GNNPLHVHHDKR 0.356 0.2080 to 0.5040 Yes ****
SGTQDSMVGWNK  vs. NAKYPTMRPGPL 0.2758 0.1278 to 0.4237 Yes ****
Wild Type vs. TAKYLPMRPGPL -0.2565 -0.4045 to -0.1085 Yes ***
Wild Type vs. DYHDPSLPTLRK -0.09375 -0.2417 to 0.05421 No ns
Wild Type vs. GNNPLHVHHDKR -0.0005 -0.1485 to 0.1475 No ns
Wild Type vs. NAKYPTMRPGPL -0.08075 -0.2287 to 0.06721 No ns
TAKYLPMRPGPL vs. DYHDPSLPTLRK 0.1628 0.01479 to 0.3107 Yes *
TAKYLPMRPGPL vs. GNNPLHVHHDKR 0.256 0.1080 to 0.4040 Yes ***
TAKYLPMRPGPL vs. NAKYPTMRPGPL 0.1758 0.02779 to 0.3237 Yes *
DYHDPSLPTLRK vs. GNNPLHVHHDKR 0.09325 -0.05471 to 0.2412 No ns
DYHDPSLPTLRK vs. NAKYPTMRPGPL 0.013 -0.1350 to 0.1610 No ns
GNNPLHVHHDKR vs. NAKYPTMRPGPL -0.08025 -0.2282 to 0.06771 No ns
1 way ANOVA for BMPR2
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary
RDYHPRDHTATW vs. SGTQDSMVGWNK -0.00125 -0.1749 to 0.1724 No ns
RDYHPRDHTATW vs. Wild Type 0.3325 0.1589 to 0.5061 Yes **




Number of families 1
Number of comparisons per family 21
Alpha 0.05
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary
Positive Control vs. KRTGQYKLGSKTGPGQK 0.09536 0.02471 to 0.1660 Yes **
Positive Control vs. VHVPLHRGAVSA 0.09931 0.02866 to 0.1700 Yes **
Positive Control vs. RDYHPRDHTATW 0.1825 0.1119 to 0.2532 Yes ****
Positive Control vs. SGTQDSMVGWNK 0.09692 0.02627 to 0.1676 Yes **
Positive Control vs. TAKYLPMRPGPL 0.1589 0.08829 to 0.2296 Yes ****
Positive Control vs. Wild Type 0.1748 0.1042 to 0.2455 Yes ****
KRTGQYKLGSKTGPGQK vs. VHVPLHRGAVSA 0.003948 -0.06670 to 0.07460 No ns
KRTGQYKLGSKTGPGQK vs. RDYHPRDHTATW 0.08718 0.01653 to 0.1578 Yes **
KRTGQYKLGSKTGPGQK vs. SGTQDSMVGWNK 0.00156 -0.06909 to 0.07221 No ns
KRTGQYKLGSKTGPGQK vs. TAKYLPMRPGPL 0.06358 -0.007073 to 0.1342 No ns
KRTGQYKLGSKTGPGQK vs. Wild Type 0.07946 0.008811 to 0.1501 Yes *
VHVPLHRGAVSA vs. RDYHPRDHTATW 0.08324 0.01259 to 0.1539 Yes *
VHVPLHRGAVSA vs. SGTQDSMVGWNK -0.002387 -0.07304 to 0.06826 No ns
VHVPLHRGAVSA vs. TAKYLPMRPGPL 0.05963 -0.01102 to 0.1303 No ns
VHVPLHRGAVSA vs. Wild Type 0.07551 0.004864 to 0.1462 Yes *
RDYHPRDHTATW vs. SGTQDSMVGWNK -0.08562 -0.1563 to -0.01497 Yes *
RDYHPRDHTATW vs. TAKYLPMRPGPL -0.02361 -0.09426 to 0.04704 No ns
RDYHPRDHTATW vs. Wild Type -0.007722 -0.07837 to 0.06293 No ns
SGTQDSMVGWNK  vs. TAKYLPMRPGPL 0.06202 -0.008634 to 0.1327 No ns
SGTQDSMVGWNK  vs. Wild Type 0.0779 0.007251 to 0.1486 Yes *
TAKYLPMRPGPL vs. Wild Type 0.01588 -0.05477 to 0.08654 No ns
Number of families 1
Number of comparisons per family 21
Alpha 0.05
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary
Positive Control vs. KRTGQYKLGSKTGPGQK 0.2476 0.1282 to 0.3670 Yes ****
Positive Control vs. VHVPLHRGAVSA 0.2424 0.1229 to 0.3618 Yes ****
Positive Control vs. RDYHPRDHTATW 0.4322 0.3128 to 0.5517 Yes ****
Positive Control vs. SGTQDSMVGWNK 0.2782 0.1588 to 0.3977 Yes ****
Positive Control vs. TAKYLPMRPGPL 0.3489 0.2295 to 0.4684 Yes ****
Positive Control vs. Wild Type 0.437 0.3176 to 0.5564 Yes ****
KRTGQYKLGSKTGPGQK vs. VHVPLHRGAVSA -0.005231 -0.1247 to 0.1142 No ns
KRTGQYKLGSKTGPGQK vs. RDYHPRDHTATW 0.1846 0.06519 to 0.3041 Yes ***
KRTGQYKLGSKTGPGQK vs. SGTQDSMVGWNK 0.03064 -0.08880 to 0.1501 No ns
KRTGQYKLGSKTGPGQK vs. TAKYLPMRPGPL 0.1013 -0.01809 to 0.2208 No ns
KRTGQYKLGSKTGPGQK vs. Wild Type 0.1894 0.06998 to 0.3089 Yes ***
VHVPLHRGAVSA vs. RDYHPRDHTATW 0.1899 0.07042 to 0.3093 Yes ***
VHVPLHRGAVSA vs. SGTQDSMVGWNK 0.03587 -0.08357 to 0.1553 No ns
VHVPLHRGAVSA vs. TAKYLPMRPGPL 0.1066 -0.01286 to 0.2260 No ns
VHVPLHRGAVSA vs. Wild Type 0.1946 0.07521 to 0.3141 Yes ***
RDYHPRDHTATW vs. SGTQDSMVGWNK -0.154 -0.2734 to -0.03455 Yes **
RDYHPRDHTATW vs. TAKYLPMRPGPL -0.08328 -0.2027 to 0.03616 No ns
RDYHPRDHTATW vs. Wild Type 0.00479 -0.1146 to 0.1242 No ns
SGTQDSMVGWNK  vs. TAKYLPMRPGPL 0.07071 -0.04873 to 0.1901 No ns
SGTQDSMVGWNK  vs. Wild Type 0.1588 0.03934 to 0.2782 Yes **
TAKYLPMRPGPL vs. Wild Type 0.08807 -0.03137 to 0.2075 No ns
1 way ANOVA for Alamar Blue 41 Hours
1 way ANOVA for Alamar Blue 71 Hours
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Supplementary Table 12. ANOVA details for alamar blue cell proliferation 
data.  
 
 
